PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"32166325","Response to Dr Braillon","Mueller S.","Alcohol Alcohol. 2020 Apr 16;55(3):338. doi: 10.1093/alcalc/agaa016.","Mueller S","Alcohol Alcohol","2020","2020/03/14","","","10.1093/alcalc/agaa016"
"32115477","[Pharmacological profile and clinical findings of nalmefene (Selincro(®)) for reducing alcohol consumption in patients with alcohol dependence]","Tadori Y.","Nihon Yakurigaku Zasshi. 2020;155(2):113-119. doi: 10.1254/fpj.19136.","Tadori Y","Nihon Yakurigaku Zasshi","2020","2020/03/03","","","10.1254/fpj.19136"
"31876051","Response to 'Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption'","Higuchi S, Miyata H, Hayashi T.","Psychiatry Clin Neurosci. 2020 Mar;74(3):219-220. doi: 10.1111/pcn.12971. Epub 2020 Jan 25.","Higuchi S","Psychiatry Clin Neurosci","2020","2019/12/27","PMC7064995","","10.1111/pcn.12971"
"31868031","Safety of nalmefene for the treatment of alcohol use disorder: an update","López-Pelayo H, Zuluaga P, Caballeria E, Van den Brink W, Mann K, Gual A.","Expert Opin Drug Saf. 2020 Jan;19(1):9-17. doi: 10.1080/14740338.2020.1707802. Epub 2019 Dec 30.","López-Pelayo H","Expert Opin Drug Saf","2020","2019/12/24","","","10.1080/14740338.2020.1707802"
"31526369","Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis","Palpacuer C, Hammas K, Duprez R, Laviolle B, Ioannidis JPA, Naudet F.","BMC Med. 2019 Sep 16;17(1):174. doi: 10.1186/s12916-019-1409-3.","Palpacuer C","BMC Med","2019","2019/09/19","PMC6747755","","10.1186/s12916-019-1409-3"
"31298784","Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial","Miyata H, Takahashi M, Murai Y, Tsuneyoshi K, Hayashi T, Meulien D, Sørensen P, Higuchi S.","Psychiatry Clin Neurosci. 2019 Nov;73(11):697-706. doi: 10.1111/pcn.12914. Epub 2019 Aug 5.","Miyata H","Psychiatry Clin Neurosci","2019","2019/07/13","PMC6899457","","10.1111/pcn.12914"
"30940694","Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose","Krieter P, Gyaw S, Crystal R, Skolnick P.","J Pharmacol Exp Ther. 2019 Nov;371(2):409-415. doi: 10.1124/jpet.118.256115. Epub 2019 Apr 2.","Krieter P","J Pharmacol Exp Ther","2019","2019/04/04","PMC6863453","","10.1124/jpet.118.256115"
"30539185","Simultaneous extraction of acidic and basic drugs via on-chip electromembrane extraction using a single-compartment microfluidic device","Zarghampour F , Yamini Y , Baharfar M , Faraji M .","Analyst. 2019 Feb 11;144(4):1159-1166. doi: 10.1039/c8an01668b.","Zarghampour F","Analyst","2019","2018/12/13","","","10.1039/c8an01668b"
"30485854","Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care","Castera P, Stewart E, Großkopf J, Brotons C, Brix Schou M, Zhang D, Steiniger Brach B, Meulien D; on behalf of the PICASO Study Investigators.","Eur Addict Res. 2018;24(6):293-303. doi: 10.1159/000494692. Epub 2018 Nov 28.","Castera P","Eur Addict Res","2018","2018/11/29","","","10.1159/000494692"
"30482648","[Drugs that require a visa, principle of equity and quality of care]","Muquebil Ali Al Shaban Rodriguez OW, Barrio Nespereira A, Álvarez Casariego MT.","J Healthc Qual Res. 2018 Nov-Dec;33(6):370-371. doi: 10.1016/j.jhqr.2018.09.003. Epub 2018 Nov 24.","Muquebil Ali Al Shaban Rodriguez OW","J Healthc Qual Res","2018","2018/11/29","","","10.1016/j.jhqr.2018.09.003"
"30421743","[Use of drugs for alcohol use disorder in Norway 2004–16]","Heldal AT, Skurtveit S, Lobmaier PPK, Vederhus JK, Bramness JG.","Tidsskr Nor Laegeforen. 2018 Nov 8;138(18). doi: 10.4045/tidsskr.18.0383. Print 2018 Nov 13.","Heldal AT","Tidsskr Nor Laegeforen","2018","2018/11/14","","","10.4045/tidsskr.18.0383"
"30290204","Short term exposure to oxycodone alters the survival, proliferation and differentiation of rat embryonic neural stem cell in vitro","Wu G, Zhao X, Wang F, Tan R, Wang J, Li X, Chen C, An J, Lu H.","Brain Res Bull. 2018 Oct;143:66-72. doi: 10.1016/j.brainresbull.2018.09.019. Epub 2018 Oct 2.","Wu G","Brain Res Bull","2018","2018/10/06","","","10.1016/j.brainresbull.2018.09.019"
"30251424","Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France","Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A.","Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1239-1248. doi: 10.1002/pds.4635. Epub 2018 Sep 25.","Chaignot C","Pharmacoepidemiol Drug Saf","2018","2018/09/26","PMC6282718","","10.1002/pds.4635"
"30197228","[Illogical association nalmefene and opioids: Analysis in the French pharmacovigilance database]","Favrelière S, Lafay-Chebassier C, Fauconneau B, Quillet A, Yéléhé-Okouma M, Montastruc F, Pérault-Pochat MC.","Therapie. 2019 Jun;74(3):369-374. doi: 10.1016/j.therap.2018.06.004. Epub 2018 Aug 3.","Favrelière S","Therapie","2019","2018/09/11","","","10.1016/j.therap.2018.06.004"
"30059574","A comparison between phase-III trials and a phase-IV study of nalmefene in alcohol use disorder patients. Is there a difference?","Barrio Giménez P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.","Adicciones. 2019 Sep 1;31(4):284-288. doi: 10.20882/adicciones.1046.","Barrio Giménez P","Adicciones","2019","2018/07/31","","","10.20882/adicciones.1046"
"30048644","Naltrexone and nalmefene attenuate cocaine place preference in male mice","Windisch KA, Reed B, Kreek MJ.","Neuropharmacology. 2018 Sep 15;140:174-183. doi: 10.1016/j.neuropharm.2018.07.025. Epub 2018 Jul 23.","Windisch KA","Neuropharmacology","2018","2018/07/27","","","10.1016/j.neuropharm.2018.07.025"
"30031019","Evaluation of alcohol use disorders pharmacotherapies in a new preclinical model of binge drinking","González-Marín MC, Lebourgeois S, Jeanblanc J, Diouf M, Naassila M.","Neuropharmacology. 2018 Sep 15;140:14-24. doi: 10.1016/j.neuropharm.2018.07.015. Epub 2018 Jul 19.","González-Marín MC","Neuropharmacology","2018","2018/07/22","","","10.1016/j.neuropharm.2018.07.015"
"29912214","Pharmacological treatment of alcohol use disorder. Scientific evidence","Attilia F, Perciballi R, Rotondo C, Capriglione I, Iannuzzi S, Attilia ML, Vitali M, Alessandrini G, Scamporrino MCM, Fiore M, Ceccanti M; Interdisciplinary Study Group CRARL - SITAC - SIPaD - SITD - SIPDip.","Riv Psichiatr. 2018 May-Jun;53(3):123-127. doi: 10.1708/2925.29414.","Attilia F","Riv Psichiatr","2018","2018/06/19","","","10.1708/2925.29414"
"29788886","Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction","Pakri Mohamed RM, Kumar J, Ahmad SU, Mohamed IN.","Curr Drug Targets. 2018;19(12):1378-1390. doi: 10.2174/1389450119666180523092534.","Pakri Mohamed RM","Curr Drug Targets","2018","2018/05/24","","","10.2174/1389450119666180523092534"
"29480453","Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?","Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.","Clin Drug Investig. 2018 Apr;38(4):387-388. doi: 10.1007/s40261-018-0625-5.","Barrio P","Clin Drug Investig","2018","2018/02/27","","","10.1007/s40261-018-0625-5"
"29479731","Severe central sleep apnoea associated with nalmefene: a case report","Khouri C, Arbib F, Revol B, Pepin JL, Tamisier R.","Br J Clin Pharmacol. 2018 May;84(5):1075-1076. doi: 10.1111/bcp.13547. Epub 2018 Feb 26.","Khouri C","Br J Clin Pharmacol","2018","2018/02/27","PMC5903229","","10.1111/bcp.13547"
"29476330","Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?","Braillon A, Taiebi F, Bernoussi A.","Clin Drug Investig. 2018 Apr;38(4):385-386. doi: 10.1007/s40261-018-0628-2.","Braillon A","Clin Drug Investig","2018","2018/02/25","","","10.1007/s40261-018-0628-2"
"29314404","Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?","Donoghue K.","Addiction. 2018 Feb;113(2):238-239. doi: 10.1111/add.14081.","Donoghue K","Addiction","2018","2018/01/10","","","10.1111/add.14081"
"29267844","Nalmefene attenuates malignant potential in colorectal cancer cell via inhibition of opioid receptor","Wu Q, Chen X, Wang J, Sun P, Weng M, Chen W, Sun Z, Zhu M, Miao C.","Acta Biochim Biophys Sin (Shanghai). 2018 Feb 1;50(2):156-163. doi: 10.1093/abbs/gmx131.","Wu Q","Acta Biochim Biophys Sin (Shanghai)","2018","2017/12/22","","","10.1093/abbs/gmx131"
"29256094","Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts","Salimi V, Mirzaei H, Ramezani A, Tahamtan A, Jamali A, Shahabi S, Golara M, Minaei B, Gharagozlou MJ, Mahmoodi M, Bont L, Shokri F, Mokhtari-Azad T.","Med Microbiol Immunol. 2018 Apr;207(2):105-115. doi: 10.1007/s00430-017-0531-0. Epub 2017 Dec 18.","Salimi V","Med Microbiol Immunol","2018","2017/12/20","","","10.1007/s00430-017-0531-0"
"29087821","Cost-Effectiveness of Nalmefene Added to Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol-Dependent Patients With High/Very High Drinking Risk Levels: A Microsimulation Model","Millier A, Laramée P, Rahhali N, Aballéa S, Daeppen JB, Rehm J, Toumi M.","J Stud Alcohol Drugs. 2017 Nov;78(6):867-876. doi: 10.15288/jsad.2017.78.867.","Millier A","J Stud Alcohol Drugs","2017","2017/11/01","","","10.15288/jsad.2017.78.867"
"29080208","Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results","Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.","Clin Drug Investig. 2018 Feb;38(2):147-155. doi: 10.1007/s40261-017-0590-4.","Barrio P","Clin Drug Investig","2018","2017/10/29","","","10.1007/s40261-017-0590-4"
"28983886","Opioid receptor antagonists in the treatment of pathological gambling","Coppola M, Mondola R.","J Opioid Manag. 2017 Jul/Aug;13(4):205-206. doi: 10.5055/jom.2017.0388.","Coppola M","J Opioid Manag","2017","2017/10/07","","","10.5055/jom.2017.0388"
"28940866","Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate","Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, Naudet F.","Addiction. 2018 Feb;113(2):220-237. doi: 10.1111/add.13974. Epub 2017 Sep 20.","Palpacuer C","Addiction","2018","2017/09/24","","","10.1111/add.13974"
"28850596","Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials","Johansen KGV, Tarp S, Astrup A, Lund H, Pagsberg AK, Christensen R.","PLoS One. 2017 Aug 29;12(8):e0183821. doi: 10.1371/journal.pone.0183821. eCollection 2017.","Johansen KGV","PLoS One","2017","2017/08/30","PMC5574613","","10.1371/journal.pone.0183821"
"28844812","Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model","Callaghan CK, Rouine J, Dean RL, Knapp BI, Bidlack JM, Deaver DR, O'Mara SM.","Brain Behav Immun. 2018 Jan;67:152-162. doi: 10.1016/j.bbi.2017.08.016. Epub 2017 Aug 24.","Callaghan CK","Brain Behav Immun","2018","2017/08/29","","","10.1016/j.bbi.2017.08.016"
"28806388","Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine","Lescut C, Gaboriau L, Carton L, Rolland B.","J Clin Psychopharmacol. 2017 Oct;37(5):631-633. doi: 10.1097/JCP.0000000000000763.","Lescut C","J Clin Psychopharmacol","2017","2017/08/15","","","10.1097/JCP.0000000000000763"
"28540656","Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study","Di Nicola M, De Filippis S, Martinotti G, De Risio L, Pettorruso M, De Persis S, Maremmani AGI, Maremmani I, di Giannantonio M, Janiri L.","Adv Ther. 2017 Jul;34(7):1636-1649. doi: 10.1007/s12325-017-0546-3. Epub 2017 May 24.","Di Nicola M","Adv Ther","2017","2017/05/26","","","10.1007/s12325-017-0546-3"
"28538998","More Treatments on Deck for Alcohol Use Disorder","Lyon J.","JAMA. 2017 Jun 13;317(22):2267-2269. doi: 10.1001/jama.2017.4760.","Lyon J","JAMA","2017","2017/05/25","","","10.1001/jama.2017.4760"
"28493563","Nalmefene Prevents Alcohol-Induced Neuroinflammation and Alcohol Drinking Preference in Adolescent Female Mice: Role of TLR4","Montesinos J, Gil A, Guerri C.","Alcohol Clin Exp Res. 2017 Jul;41(7):1257-1270. doi: 10.1111/acer.13416. Epub 2017 Jun 5.","Montesinos J","Alcohol Clin Exp Res","2017","2017/05/12","","","10.1111/acer.13416"
"28376679","Dopamine and μ-opioid receptor dysregulation in the brains of binge-eating female rats - possible relevance in the psychopathology and treatment of binge-eating disorder","Heal DJ, Hallam M, Prow M, Gosden J, Cheetham S, Choi YK, Tarazi F, Hutson P.","J Psychopharmacol. 2017 Jun;31(6):770-783. doi: 10.1177/0269881117699607. Epub 2017 Apr 5.","Heal DJ","J Psychopharmacol","2017","2017/04/06","","","10.1177/0269881117699607"
"28343423","Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians","Franchitto N, Jullian B, Salles J, Pelissier F, Rolland B.","Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):669-677. doi: 10.1080/17425255.2017.1312340. Epub 2017 Apr 3.","Franchitto N","Expert Opin Drug Metab Toxicol","2017","2017/03/28","","","10.1080/17425255.2017.1312340"
"28322465","Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine","Yéléhé-Okouma M, Martini H, Lemarié J, Labroca P, Petitpain N, Gibaja V, Paille F, Gillet P.","Fundam Clin Pharmacol. 2017 Oct;31(5):574-579. doi: 10.1111/fcp.12286. Epub 2017 May 9.","Yéléhé-Okouma M","Fundam Clin Pharmacol","2017","2017/03/22","","","10.1111/fcp.12286"
"28220511","Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore","Goh ET, Morgan MY.","Aliment Pharmacol Ther. 2017 Apr;45(7):865-882. doi: 10.1111/apt.13965. Epub 2017 Feb 20.","Goh ET","Aliment Pharmacol Ther","2017","2017/02/22","","","10.1111/apt.13965"
"28219609","Neuroscience in gambling policy and treatment: an interdisciplinary perspective","Yücel M, Carter A, Allen AR, Balleine B, Clark L, Dowling NA, Gainsbury SM, Goudriaan AE, Grant J, Hayes A, Hodgins D, van Holst R, Lattimore R, Livingstone C, Lorenzetti V, Lubman D, Murawski C, Parkes L, Petry N, Room R, Singh B, Thomas A, Townshend P, Youssef G, Hall W.","Lancet Psychiatry. 2017 Jun;4(6):501-506. doi: 10.1016/S2215-0366(16)30369-8. Epub 2017 Feb 15.","Yücel M","Lancet Psychiatry","2017","2017/02/22","","","10.1016/S2215-0366(16)30369-8"
"28216062","Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study","Quelch DR, Mick I, McGonigle J, Ramos AC, Flechais RSA, Bolstridge M, Rabiner E, Wall MB, Newbould RD, Steiniger-Brach B, van den Berg F, Boyce M, Østergaard Nilausen D, Breuning Sluth L, Meulien D, von der Goltz C, Nutt D, Lingford-Hughes A.","Biol Psychiatry. 2017 Jun 1;81(11):941-948. doi: 10.1016/j.biopsych.2016.12.029. Epub 2017 Jan 10.","Quelch DR","Biol Psychiatry","2017","2017/02/21","","","10.1016/j.biopsych.2016.12.029"
"28181957","Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report","Martín-Blanco A, Patrizi B, Soler J, Gasol X, Elices M, Gasol M, Carmona C, Pascual JC.","Int Clin Psychopharmacol. 2017 Jul;32(4):231-234. doi: 10.1097/YIC.0000000000000170.","Martín-Blanco A","Int Clin Psychopharmacol","2017","2017/02/10","","","10.1097/YIC.0000000000000170"
"27889007","Nalmefene for alcohol dependence: a NICE decision?","Naudet F, Fitzgerald N, Braillon A.","Lancet Psychiatry. 2016 Dec;3(12):1104-1105. doi: 10.1016/S2215-0366(16)30356-X.","Naudet F","Lancet Psychiatry","2016","2016/11/28","","","10.1016/S2215-0366(16)30356-X"
"27842940","Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","Mann K, Torup L, Sørensen P, Gual A, Swift R, Walker B, van den Brink W.","Eur Neuropsychopharmacol. 2016 Dec;26(12):1941-1949. doi: 10.1016/j.euroneuro.2016.10.008. Epub 2016 Nov 12.","Mann K","Eur Neuropsychopharmacol","2016","2016/11/16","","","10.1016/j.euroneuro.2016.10.008"
"27609425","▼Nalmefene-time for last orders?","","Drug Ther Bull. 2016 Sep;54(9):97. doi: 10.1136/dtb.2016.9.0421.","","Drug Ther Bull","2016","2016/09/10","","","10.1136/dtb.2016.9.0421"
"27534932","Evaluation in alcohol use disorders - insights from the nalmefene experience","Naudet F, Palpacuer C, Boussageon R, Laviolle B.","BMC Med. 2016 Aug 18;14(1):119. doi: 10.1186/s12916-016-0664-9.","Naudet F","BMC Med","2016","2016/08/19","PMC4989362","","10.1186/s12916-016-0664-9"
"27472317","Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure","Rose JH, Karkhanis AN, Steiniger-Brach B, Jones SR.","Int J Mol Sci. 2016 Jul 27;17(8):1216. doi: 10.3390/ijms17081216.","Rose JH","Int J Mol Sci","2016","2016/07/30","PMC5000614","","10.3390/ijms17081216"
"27470429","A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence","Laramée P, Millier A, Brodtkorb TH, Rahhali N, Cristeau O, Aballéa S, Montgomery S, Steeves S, Toumi M, Rehm J.","Clin Drug Investig. 2016 Nov;36(11):945-956. doi: 10.1007/s40261-016-0442-7.","Laramée P","Clin Drug Investig","2016","2016/07/30","","","10.1007/s40261-016-0442-7"
"27438908","Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe","Bramness JG, Mann K, Wurst FM.","Eur Addict Res. 2016;22(6):318-321. doi: 10.1159/000447965. Epub 2016 Jul 21.","Bramness JG","Eur Addict Res","2016","2016/07/21","","","10.1159/000447965"
"27388713","Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-analysis - Comment to Naudet","Soyka M, Friede M, Schnitker J.","Pharmacopsychiatry. 2016 Nov;49(6):261-262. doi: 10.1055/s-0042-110494. Epub 2016 Jul 7.","Soyka M","Pharmacopsychiatry","2016","2016/07/09","","","10.1055/s-0042-110494"
"27388712","Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin?","Naudet F.","Pharmacopsychiatry. 2016 Nov;49(6):260-261. doi: 10.1055/s-0042-110493. Epub 2016 Jul 7.","Naudet F","Pharmacopsychiatry","2016","2016/07/09","","","10.1055/s-0042-110493"
"27283839","A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence","Laramée P, Millier A, Rahhali N, Cristeau O, Aballéa S, François C, Chalem Y, Toumi M, Rehm J.","Appl Health Econ Health Policy. 2016 Aug;14(4):493-505. doi: 10.1007/s40258-016-0248-z.","Laramée P","Appl Health Econ Health Policy","2016","2016/06/11","","","10.1007/s40258-016-0248-z"
"27262594","Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers","Fitzgerald N, Angus K, Elders A, de Andrade M, Raistrick D, Heather N, McCambridge J.","Addiction. 2016 Aug;111(8):1477-87. doi: 10.1111/add.13438. Epub 2016 Jun 5.","Fitzgerald N","Addiction","2016","2016/06/06","PMC5089629","","10.1111/add.13438"
"27261473","Cost-Effectiveness of Nalmefene: Exaggerated Expectations or Fallacy?","Naudet F, Granger B, Braillon A.","Alcohol Alcohol. 2016 Sep;51(5):623-4. doi: 10.1093/alcalc/agw029. Epub 2016 Jun 3.","Naudet F","Alcohol Alcohol","2016","2016/06/05","","","10.1093/alcalc/agw029"
"27238566","Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood","Calleja-Conde J, Echeverry-Alzate V, Giné E, Bühler KM, Nadal R, Maldonado R, Rodríguez de Fonseca F, Gual A, López-Moreno JA.","Br J Pharmacol. 2016 Aug;173(16):2490-505. doi: 10.1111/bph.13526. Epub 2016 Jul 18.","Calleja-Conde J","Br J Pharmacol","2016","2016/05/31","PMC4959953","","10.1111/bph.13526"
"27107723","Lipophilic nalmefene prodrugs to achieve a one-month sustained release","Gaekens T, Guillaume M, Borghys H, De Zwart LL, de Vries R, Embrechts RC, Vermeulen A, Megens AA, Leysen JE, Herdewijn P, Annaert PP, Atack JR.","J Control Release. 2016 Jun 28;232:196-202. doi: 10.1016/j.jconrel.2016.04.029. Epub 2016 Apr 21.","Gaekens T","J Control Release","2016","2016/04/25","","","10.1016/j.jconrel.2016.04.029"
"26990998","Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors","Korpi ER, Linden AM, Hytönen HR, Paasikoski N, Vashchinkina E, Dudek M, Herr DR, Hyytiä P.","Addict Biol. 2017 Jul;22(4):1022-1035. doi: 10.1111/adb.12393. Epub 2016 Mar 15.","Korpi ER","Addict Biol","2017","2016/03/19","","","10.1111/adb.12393"
"26879458","The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective","Brodtkorb TH, Bell M, Irving AH, Laramée P.","CNS Drugs. 2016 Feb;30(2):163-77. doi: 10.1007/s40263-016-0310-2.","Brodtkorb TH","CNS Drugs","2016","2016/02/17","","","10.1007/s40263-016-0310-2"
"26860331","Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series","Caputo F, Maremmani AG, Addolorato G, Domenicali M, Zoli G, D'Amore A, Maremmani I, Bernardi M.","J Psychopharmacol. 2016 Apr;30(4):402-9. doi: 10.1177/0269881116629126. Epub 2016 Feb 9.","Caputo F","J Psychopharmacol","2016","2016/02/11","","","10.1177/0269881116629126"
"26845589","Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis","Soyka M, Friede M, Schnitker J.","Pharmacopsychiatry. 2016 Mar;49(2):66-75. doi: 10.1055/s-0035-1565184. Epub 2016 Feb 4.","Soyka M","Pharmacopsychiatry","2016","2016/02/05","","","10.1055/s-0035-1565184"
"26825639","The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol Dependence","Laramée P, Bell M, Irving A, Brodtkorb TH.","Alcohol Alcohol. 2016 May;51(3):283-90. doi: 10.1093/alcalc/agv140. Epub 2016 Jan 28.","Laramée P","Alcohol Alcohol","2016","2016/01/31","","","10.1093/alcalc/agv140"
"26810044","Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential","Soyka M.","Expert Opin Pharmacother. 2016;17(4):619-26. doi: 10.1517/14656566.2016.1146689. Epub 2016 Feb 16.","Soyka M","Expert Opin Pharmacother","2016","2016/01/27","","","10.1517/14656566.2016.1146689"
"26798982","Opioid antagonists in broadly defined behavioral addictions: a narrative review","Piquet-Pessôa M, Fontenelle LF.","Expert Opin Pharmacother. 2016;17(6):835-44. doi: 10.1517/14656566.2016.1145660. Epub 2016 Feb 27.","Piquet-Pessôa M","Expert Opin Pharmacother","2016","2016/01/23","","","10.1517/14656566.2016.1145660"
"26714742","Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder","Milano G, Zavan V, Natta WM, Martelli A, Mattioli F.","J Clin Pharm Ther. 2016 Feb;41(1):97-100. doi: 10.1111/jcpt.12345. Epub 2015 Dec 30.","Milano G","J Clin Pharm Ther","2016","2015/12/31","","","10.1111/jcpt.12345"
"26694529","Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials","Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F.","PLoS Med. 2015 Dec 22;12(12):e1001924. doi: 10.1371/journal.pmed.1001924. eCollection 2015 Dec.","Palpacuer C","PLoS Med","2015","2015/12/24","PMC4687857","","10.1371/journal.pmed.1001924"
"26658085","Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting","Pélissier F, Rougé Bugat ME, Nubukpo P, Franchitto N.","J Clin Psychopharmacol. 2016 Feb;36(1):100-3. doi: 10.1097/JCP.0000000000000448.","Pélissier F","J Clin Psychopharmacol","2016","2015/12/15","","","10.1097/JCP.0000000000000448"
"26589243","Effects of lisdexamfetamine in a rat model of binge-eating","Vickers SP, Hackett D, Murray F, Hutson PH, Heal DJ.","J Psychopharmacol. 2015 Dec;29(12):1290-307. doi: 10.1177/0269881115615107. Epub 2015 Nov 20.","Vickers SP","J Psychopharmacol","2015","2015/11/22","","","10.1177/0269881115615107"
"26583653","Effectiveness of Nalmefene in Binge Eating Disorder: A Case Report","Marazziti D, Piccinni A, Baroni S, DellʼOsso L.","J Clin Psychopharmacol. 2016 Feb;36(1):103-4. doi: 10.1097/JCP.0000000000000427.","Marazziti D","J Clin Psychopharmacol","2016","2015/11/20","","","10.1097/JCP.0000000000000427"
"26525810","[Alcohol use disorders: current approaches to diagnosis and treatment]","Sivolap YP.","Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(9):23-27. doi: 10.17116/jnevro20151159123-27.","Sivolap YP","Zh Nevrol Psikhiatr Im S S Korsakova","2015","2015/11/04","","","10.17116/jnevro20151159123-27"
"26483076","Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy","Kyhl LE, Li S, Faerch KU, Soegaard B, Larsen F, Areberg J.","Br J Clin Pharmacol. 2016 Feb;81(2):290-300. doi: 10.1111/bcp.12805. Epub 2016 Jan 27.","Kyhl LE","Br J Clin Pharmacol","2016","2015/10/21","PMC4833148","","10.1111/bcp.12805"
"26463904","[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions]","Dahmke H, Kupferschmidt H, Kullak-Ublick GA, Weiler S.","Praxis (Bern 1994). 2015 Oct 14;104(21):1129-34. doi: 10.1024/1661-8157/a002160.","Dahmke H","Praxis (Bern 1994)","2015","2015/10/15","","","10.1024/1661-8157/a002160"
"26437315","Opioid Receptor Antagonists in the Treatment of Alcoholism","Serecigni JG.","Adicciones. 2015 Sep 29;27(3):214-30.","Serecigni JG","Adicciones","2015","2015/10/06","","",""
"26410545","The T-peak-T-end interval as a marker of repolarization abnormality: a comparison with the QT interval for five different drugs","Bhuiyan TA, Graff C, Kanters JK, Nielsen J, Melgaard J, Matz J, Toft E, Struijk JJ.","Clin Drug Investig. 2015 Nov;35(11):717-24. doi: 10.1007/s40261-015-0328-0.","Bhuiyan TA","Clin Drug Investig","2015","2015/09/28","","","10.1007/s40261-015-0328-0"
"26394517","[Pharmacological therapies for alcohol use disorder in Japan]","Yumoto Y, Higuchi S.","Nihon Rinsho. 2015 Sep;73(9):1536-9.","Yumoto Y","Nihon Rinsho","2015","2015/09/24","","",""
"26364383","[Reduction of consumption as the first goal of therapy]","Bruhn C.","Med Monatsschr Pharm. 2015 Apr;38(4):145-6.","Bruhn C","Med Monatsschr Pharm","2015","2015/09/15","","",""
"26349557","Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk","Roerecke M, Sørensen P, Laramée P, Rahhali N, Rehm J.","J Psychopharmacol. 2015 Nov;29(11):1152-8. doi: 10.1177/0269881115602487. Epub 2015 Sep 8.","Roerecke M","J Psychopharmacol","2015","2015/09/10","PMC4623485","","10.1177/0269881115602487"
"26314552","Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review","Agabio R, Pani PP, Preti A, Gessa GL, Franconi F.","Eur Addict Res. 2016;22(1):1-16. doi: 10.1159/000433579. Epub 2015 Aug 29.","Agabio R","Eur Addict Res","2016","2015/08/29","","","10.1159/000433579"
"26295464","Nalmefene: A Novel Drug for an Old Disorder","Marazziti D, Presta S, Baroni S, Mungai F, Piccinni A, Mucci F, Dell'Osso L.","Curr Med Chem. 2015;22(27):3162-8. doi: 10.2174/0929867322666150821100538.","Marazziti D","Curr Med Chem","2015","2015/08/22","","","10.2174/0929867322666150821100538"
"26053024","The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients","François C, Rahhali N, Chalem Y, Sørensen P, Luquiens A, Aubin HJ.","PLoS One. 2015 Jun 8;10(6):e0129289. doi: 10.1371/journal.pone.0129289. eCollection 2015.","François C","PLoS One","2015","2015/06/09","PMC4460126","","10.1371/journal.pone.0129289"
"26050241","Severe opioid withdrawal syndrome after a single dose of nalmefene","Donnerstag N, Schneider T, Lüthi A, Taegtmeyer A, Raetz Bravo A, Mehlig A.","Eur J Clin Pharmacol. 2015 Aug;71(8):1025-6. doi: 10.1007/s00228-015-1884-1. Epub 2015 Jun 7.","Donnerstag N","Eur J Clin Pharmacol","2015","2015/06/08","","","10.1007/s00228-015-1884-1"
"26021148","[Influence of nalmefene on psychosocial intervention in alcohol-dependent patients]","Favrod-Coune T.","Rev Med Suisse. 2015 Apr 1;11(468):792.","Favrod-Coune T","Rev Med Suisse","2015","2015/05/30","","",""
"25938514","In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene","Xie X, Lin W, Xing C, Yang Y, Chi Q, Zhang H, Li Y, Li Z, Yang Y, Yang Z, Li M.","PLoS One. 2015 May 4;10(5):e0125953. doi: 10.1371/journal.pone.0125953. eCollection 2015.","Xie X","PLoS One","2015","2015/05/05","PMC4418713","","10.1371/journal.pone.0125953"
"25851485","Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J, Morgan MY.","Pharmacoeconomics. 2015 Aug;33(8):833-47. doi: 10.1007/s40273-015-0272-0.","Stevenson M","Pharmacoeconomics","2015","2015/04/09","","","10.1007/s40273-015-0272-0"
"25832297","Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients","Aubin HJ, Reimer J, Nutt DJ, Bladström A, Torup L, François C, Chick J.","Eur Addict Res. 2015;21(3):160-8. doi: 10.1159/000371547. Epub 2015 Mar 31.","Aubin HJ","Eur Addict Res","2015","2015/04/03","","","10.1159/000371547"
"25805351","[Neurobiology of alcohol and pharmacological aspects of nalmefene]","Biggio G.","Riv Psichiatr. 2015 Jan-Feb;50(1):19-27. doi: 10.1708/1794.19530.","Biggio G","Riv Psichiatr","2015","2015/03/26","","","10.1708/1794.19530"
"25761458","Recent Developments in Pharmacotherapy of Alcoholism","Soyka M, Lieb M.","Pharmacopsychiatry. 2015 Jul;48(4-5):123-35. doi: 10.1055/s-0035-1547237. Epub 2015 Mar 11.","Soyka M","Pharmacopsychiatry","2015","2015/03/13","","","10.1055/s-0035-1547237"
"25652768","Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme","van den Brink W, Strang J, Gual A, Sørensen P, Jensen TJ, Mann K.","Expert Opin Drug Saf. 2015 Apr;14(4):495-504. doi: 10.1517/14740338.2015.1011619. Epub 2015 Feb 4.","van den Brink W","Expert Opin Drug Saf","2015","2015/02/06","","","10.1517/14740338.2015.1011619"
"25647453","Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience","Grosshans M, Mutschler J, Kiefer F.","Int Clin Psychopharmacol. 2015 Jul;30(4):237-8. doi: 10.1097/YIC.0000000000000069.","Grosshans M","Int Clin Psychopharmacol","2015","2015/02/04","","","10.1097/YIC.0000000000000069"
"25562928","[Nalmefene (Selincro) orally]","","J Pharm Belg. 2014 Dec;(4):51-2.","","J Pharm Belg","2014","2015/01/08","","",""
"25487784","German evaluation says new drug for alcohol dependence is no better than old one","Stafford N.","BMJ. 2014 Dec 8;349:g7544. doi: 10.1136/bmj.g7544.","Stafford N","BMJ","2014","2014/12/10","","","10.1136/bmj.g7544"
"25454365","[Benefits in reducing alcohol consumption: how nalmefene can help]","Bendimerad P, Blecha L.","Encephale. 2014 Dec;40(6):495-500. doi: 10.1016/j.encep.2014.10.012. Epub 2014 Nov 22.","Bendimerad P","Encephale","2014","2014/12/03","","","10.1016/j.encep.2014.10.012"
"25454364","[Place of the opioid system in biology and treatment of Alcohol Use Disorder]","Nubukpo P.","Encephale. 2014 Dec;40(6):457-67. doi: 10.1016/j.encep.2014.10.010. Epub 2014 Nov 22.","Nubukpo P","Encephale","2014","2014/12/03","","","10.1016/j.encep.2014.10.010"
"25442002","A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice","Bilbao A, Robinson JE, Heilig M, Malanga CJ, Spanagel R, Sommer WH, Thorsell A.","Biol Psychiatry. 2015 May 15;77(10):850-8. doi: 10.1016/j.biopsych.2014.08.021. Epub 2014 Sep 8.","Bilbao A","Biol Psychiatry","2015","2014/12/03","","","10.1016/j.biopsych.2014.08.021"
"25392958","Treatment of alcohol dependence: recent progress and reduction of consumption","Testino G, Leone S, Borro P.","Minerva Med. 2014 Dec;105(6):447-66.","Testino G","Minerva Med","2014","2014/11/14","","",""
"25375267","Neuroprotection of nalmefene for postoperative patients with spontaneous intracerebral hemorrhage","Zheng J, Li H, Guo R, Chen R, Lin S, Liu M, You C.","Int J Neurosci. 2015;125(12):918-23. doi: 10.3109/00207454.2014.985294. Epub 2014 Dec 3.","Zheng J","Int J Neurosci","2015","2014/11/07","","","10.3109/00207454.2014.985294"
"25287870","Decision to recommend drug to cut drink dependence proves controversial","Wise J.","BMJ. 2014 Oct 5;349:g6054. doi: 10.1136/bmj.g6054.","Wise J","BMJ","2014","2014/10/08","","","10.1136/bmj.g6054"
"25228120","A predictive microsimulation model to estimate the clinical relevance of reducing alcohol consumption in alcohol dependence","François C, Laramée P, Rahhali N, Chalem Y, Aballéa S, Millier A, Bineau S, Toumi M, Rehm J.","Eur Addict Res. 2014;20(6):269-84. doi: 10.1159/000362408. Epub 2014 Sep 16.","François C","Eur Addict Res","2014","2014/09/18","","","10.1159/000362408"
"25227627","The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model","Laramée P, Brodtkorb TH, Rahhali N, Knight C, Barbosa C, François C, Toumi M, Daeppen JB, Rehm J.","BMJ Open. 2014 Sep 16;4(9):e005376. doi: 10.1136/bmjopen-2014-005376.","Laramée P","BMJ Open","2014","2014/09/18","PMC4166142","","10.1136/bmjopen-2014-005376"
"25121147","Nalmefene. Alcohol dependence: no advance","","Prescrire Int. 2014 Jun;23(150):150-2.","","Prescrire Int","2014","2014/08/15","","",""
"24973897","The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours","Kelly E, Mundell SJ, Sava A, Roth AL, Felici A, Maltby K, Nathan PJ, Bullmore ET, Henderson G.","Psychopharmacology (Berl). 2015 Jan;232(1):305-14. doi: 10.1007/s00213-014-3666-3. Epub 2014 Jun 29.","Kelly E","Psychopharmacology (Berl)","2015","2014/06/30","PMC4281354","","10.1007/s00213-014-3666-3"
"24918835","Nalmefene and its use in alcohol dependence","Gual A, Bruguera P, López-Pelayo H.","Drugs Today (Barc). 2014 May;50(5):347-55. doi: 10.1358/dot.2014.50.5.2132323.","Gual A","Drugs Today (Barc)","2014","2014/06/12","","","10.1358/dot.2014.50.5.2132323"
"24886878","Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats","Yong Z, Gao X, Ma W, Dong H, Gong Z, Su R.","Eur J Pharmacol. 2014 Sep 5;738:153-7. doi: 10.1016/j.ejphar.2014.05.044. Epub 2014 Jun 2.","Yong Z","Eur J Pharmacol","2014","2014/06/03","","","10.1016/j.ejphar.2014.05.044"
"24825644","Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC.","JAMA. 2014 May 14;311(18):1889-900. doi: 10.1001/jama.2014.3628.","Jonas DE","JAMA","2014","2014/05/15","","","10.1001/jama.2014.3628"
"24809337","▼Nalmefene for alcohol dependence","","Drug Ther Bull. 2014 May;52(5):54-7. doi: 10.1136/dtb.2014.5.0252. Epub 2014 May 8.","","Drug Ther Bull","2014","2014/05/10","","","10.1136/dtb.2014.5.0252"
"24671340","Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study","van den Brink W, Sørensen P, Torup L, Mann K, Gual A; SENSE Study Group.","J Psychopharmacol. 2014 Aug;28(8):733-44. doi: 10.1177/0269881114527362. Epub 2014 Mar 26.","van den Brink W","J Psychopharmacol","2014","2014/03/28","","","10.1177/0269881114527362"
"24614808","Bad medicine: using surrogate markers","McNulty SJ, Williams P.","BMJ. 2014 Mar 10;348:g2012. doi: 10.1136/bmj.g2012.","McNulty SJ","BMJ","2014","2014/03/12","","","10.1136/bmj.g2012"
"24614566","Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency","Braillon A.","BMJ. 2014 Mar 10;348:g2017. doi: 10.1136/bmj.g2017.","Braillon A","BMJ","2014","2014/03/12","","","10.1136/bmj.g2017"
"24557083","Can alcohol dependent patients adhere to an 'as-needed' medication regimen?","Sinclair J, Chick J, Sørensen P, Kiefer F, Batel P, Gual A.","Eur Addict Res. 2014;20(5):209-17. doi: 10.1159/000357865. Epub 2014 Feb 15.","Sinclair J","Eur Addict Res","2014","2014/02/22","","","10.1159/000357865"
"24531208","Bad medicine: nalmefene in alcohol misuse","Spence D.","BMJ. 2014 Feb 14;348:g1531. doi: 10.1136/bmj.g1531.","Spence D","BMJ","2014","2014/02/18","","","10.1136/bmj.g1531"
"24437142","[New treatment options for alcohol dependence]","Müller CA, Heinz A.","MMW Fortschr Med. 2013 May 2;155(8):63-5. doi: 10.1007/s15006-013-0644-3.","Müller CA","MMW Fortschr Med","2013","2014/01/21","","","10.1007/s15006-013-0644-3"
"24246244","Nalmefene for the treatment of alcohol dependence: a current update","Soyka M.","Int J Neuropsychopharmacol. 2014 Apr;17(4):675-84. doi: 10.1017/S1461145713001284. Epub 2013 Nov 18.","Soyka M","Int J Neuropsychopharmacol","2014","2013/11/20","","","10.1017/S1461145713001284"
"24126432","[Nalmefene: a novel pharmacotherapeutic option for alcoholism]","Soyka M.","Nervenarzt. 2014 May;85(5):578-82. doi: 10.1007/s00115-013-3843-3.","Soyka M","Nervenarzt","2014","2013/10/16","","","10.1007/s00115-013-3843-3"
"23949908","Nalmefene: a review of its use in the treatment of alcohol dependence","Keating GM.","CNS Drugs. 2013 Sep;27(9):761-72. doi: 10.1007/s40263-013-0101-y.","Keating GM","CNS Drugs","2013","2013/08/17","","","10.1007/s40263-013-0101-y"
"23881605","Targeted opioid receptor antagonists in the treatment of alcohol use disorders","Niciu MJ, Arias AJ.","CNS Drugs. 2013 Oct;27(10):777-87. doi: 10.1007/s40263-013-0096-4.","Niciu MJ","CNS Drugs","2013","2013/07/25","PMC4600601","NIHMS509129","10.1007/s40263-013-0096-4"
"23873853","Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","van den Brink W, Aubin HJ, Bladström A, Torup L, Gual A, Mann K.","Alcohol Alcohol. 2013 Sep-Oct;48(5):570-8. doi: 10.1093/alcalc/agt061. Epub 2013 Jul 19.","van den Brink W","Alcohol Alcohol","2013","2013/07/23","PMC3746807","","10.1093/alcalc/agt061"
"23810221","Pharmacotherapy for alcohol dependence: status of current treatments","Franck J, Jayaram-Lindström N.","Curr Opin Neurobiol. 2013 Aug;23(4):692-9. doi: 10.1016/j.conb.2013.05.005. Epub 2013 Jun 26.","Franck J","Curr Opin Neurobiol","2013","2013/07/02","","","10.1016/j.conb.2013.05.005"
"23746430","Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption","Aubin HJ, Daeppen JB.","Drug Alcohol Depend. 2013 Nov 1;133(1):15-29. doi: 10.1016/j.drugalcdep.2013.04.025. Epub 2013 Jun 6.","Aubin HJ","Drug Alcohol Depend","2013","2013/06/11","","","10.1016/j.drugalcdep.2013.04.025"
"23562264","A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group.","Eur Neuropsychopharmacol. 2013 Nov;23(11):1432-42. doi: 10.1016/j.euroneuro.2013.02.006. Epub 2013 Apr 3.","Gual A","Eur Neuropsychopharmacol","2013","2013/04/09","","","10.1016/j.euroneuro.2013.02.006"
"23540350","Naltrexone and nalmefene: any meaningful difference?","Swift RM.","Biol Psychiatry. 2013 Apr 15;73(8):700-1. doi: 10.1016/j.biopsych.2013.03.002.","Swift RM","Biol Psychiatry","2013","2013/04/02","","","10.1016/j.biopsych.2013.03.002"
"23237314","Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","Mann K, Bladström A, Torup L, Gual A, van den Brink W.","Biol Psychiatry. 2013 Apr 15;73(8):706-13. doi: 10.1016/j.biopsych.2012.10.020. Epub 2012 Dec 11.","Mann K","Biol Psychiatry","2013","2012/12/15","","","10.1016/j.biopsych.2012.10.020"
"23222260","Opioid receptors control viral replication in the airways","Salimi V, Hennus MP, Mokhtari-Azad T, Shokri F, Janssen R, Hodemaekers HM, Rygiel TP, Coenjaerts FE, Meyaard L, Bont L.","Crit Care Med. 2013 Jan;41(1):205-14. doi: 10.1097/CCM.0b013e31826767a8.","Salimi V","Crit Care Med","2013","2012/12/11","","","10.1097/CCM.0b013e31826767a8"
"22999198","Pulsed electromembrane extraction: a new concept of electrically enhanced extraction","Rezazadeh M, Yamini Y, Seidi S, Esrafili A.","J Chromatogr A. 2012 Nov 2;1262:214-8. doi: 10.1016/j.chroma.2012.08.090. Epub 2012 Sep 3.","Rezazadeh M","J Chromatogr A","2012","2012/09/25","","","10.1016/j.chroma.2012.08.090"
"22575744","Low-voltage electrically-enhanced microextraction as a novel technique for simultaneous extraction of acidic and basic drugs from biological fluids","Seidi S, Yamini Y, Rezazadeh M, Esrafili A.","J Chromatogr A. 2012 Jun 22;1243:6-13. doi: 10.1016/j.chroma.2012.04.050. Epub 2012 Apr 26.","Seidi S","J Chromatogr A","2012","2012/05/12","","","10.1016/j.chroma.2012.04.050"
"22389180","New pharmacological treatment strategies for relapse prevention","Spanagel R, Vengeliene V.","Curr Top Behav Neurosci. 2013;13:583-609. doi: 10.1007/7854_2012_205.","Spanagel R","Curr Top Behav Neurosci","2013","2012/03/06","","","10.1007/7854_2012_205"
"22078567","Structural basis for μ-opioid receptor binding and activation","Serohijos AW, Yin S, Ding F, Gauthier J, Gibson DG, Maixner W, Dokholyan NV, Diatchenko L.","Structure. 2011 Nov 9;19(11):1683-90. doi: 10.1016/j.str.2011.08.003.","Serohijos AW","Structure","2011","2011/11/15","PMC3217204","NIHMS319188","10.1016/j.str.2011.08.003"
"22046937","Opioid antagonists for the treatment of alcohol dependence","Yancey JR, Lumbad J.","Am Fam Physician. 2011 Nov 1;84(9):990-2.","Yancey JR","Am Fam Physician","2011","2011/11/04","","",""
"21967071","Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study","Matz J, Graff C, Vainio PJ, Kallio A, Højer AM, Struijk JJ, Kanters JK, Andersen MP, Toft E.","Clin Drug Investig. 2011 Nov 1;31(11):799-811. doi: 10.1007/BF03256919.","Matz J","Clin Drug Investig","2011","2011/10/05","","","10.1007/BF03256919"
"21818506","A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis","Herzog JL, Solomon JA, Draelos Z, Fleischer A Jr, Stough D, Wolf DI, Abramovits W, Werschler W, Green E, Duffy M, Rothaul A, Tansley R.","J Drugs Dermatol. 2011 Aug;10(8):853-60.","Herzog JL","J Drugs Dermatol","2011","2011/08/06","","",""
"21804585","Trial watch: Nalmefene reduces alcohol use in phase III trial","","Nat Rev Drug Discov. 2011 Aug 1;10(8):566. doi: 10.1038/nrd3518.","","Nat Rev Drug Discov","2011","2011/08/02","","","10.1038/nrd3518"
"21493167","Electromembrane extraction of trace amounts of naltrexone and nalmefene from untreated biological fluids","Rezazadeh M, Yamini Y, Seidi S.","J Chromatogr B Analyt Technol Biomed Life Sci. 2011 May 1;879(15-16):1143-8. doi: 10.1016/j.jchromb.2011.03.043. Epub 2011 Mar 30.","Rezazadeh M","J Chromatogr B Analyt Technol Biomed Life Sci","2011","2011/04/16","","","10.1016/j.jchromb.2011.03.043"
"21338616","κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats","Nealey KA, Smith AW, Davis SM, Smith DG, Walker BM.","Neuropharmacology. 2011 Jul-Aug;61(1-2):35-42. doi: 10.1016/j.neuropharm.2011.02.012. Epub 2011 Feb 19.","Nealey KA","Neuropharmacology","2011","2011/02/23","PMC3955175","NIHMS572167","10.1016/j.neuropharm.2011.02.012"
"21291870","Opioid-like compound exerts anti-fibrotic activity via decreased hepatic stellate cell activation and inflammation","Day SA, Lakner AM, Moore CC, Yen MH, Clemens MG, Wu ES, Schrum LW.","Biochem Pharmacol. 2011 Apr 15;81(8):996-1003. doi: 10.1016/j.bcp.2011.01.015. Epub 2011 Feb 1.","Day SA","Biochem Pharmacol","2011","2011/02/05","","","10.1016/j.bcp.2011.01.015"
"21154349","Opioid antagonists for alcohol dependence","Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M.","Cochrane Database Syst Rev. 2010 Dec 8;(12):CD001867. doi: 10.1002/14651858.CD001867.pub2.","Rösner S","Cochrane Database Syst Rev","2010","2010/12/15","","","10.1002/14651858.CD001867.pub2"
"21083993","[Serum NT-proBNP levels in neonates with severe asphyxia and the effects of nalmefene on the NT-proBNP levels]","Zhang Q, Cheng XR, Sheng GY.","Zhongguo Dang Dai Er Ke Za Zhi. 2010 Nov;12(11):922-3.","Zhang Q","Zhongguo Dang Dai Er Ke Za Zhi","2010","2010/11/19","","",""
"20884959","Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study","Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW.","Br J Psychiatry. 2010 Oct;197(4):330-1. doi: 10.1192/bjp.bp.110.078105.","Grant JE","Br J Psychiatry","2010","2010/10/02","","","10.1192/bjp.bp.110.078105"
"20868291","Nalmefene for treatment of alcohol dependence","Soyka M, Rösner S.","Expert Opin Investig Drugs. 2010 Nov;19(11):1451-9. doi: 10.1517/13543784.2010.522990. Epub 2010 Sep 25.","Soyka M","Expert Opin Investig Drugs","2010","2010/09/28","","","10.1517/13543784.2010.522990"
"20594468","[Clinical observation of the effect of nalmefene in treatment of septic shock]","Wang HL, Yu KJ, Liu HT.","Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2010 Jun;22(6):351-3.","Wang HL","Zhongguo Wei Zhong Bing Ji Jiu Yi Xue","2010","2010/07/03","","",""
"20462660","Antipruritic treatment with systemic μ-opioid receptor antagonists: a review","Phan NQ, Bernhard JD, Luger TA, Ständer S.","J Am Acad Dermatol. 2010 Oct;63(4):680-8. doi: 10.1016/j.jaad.2009.08.052. Epub 2010 May 11.","Phan NQ","J Am Acad Dermatol","2010","2010/05/14","","","10.1016/j.jaad.2009.08.052"
"20159022","In vivo characterization of the opioid antagonist nalmefene in mice","Osborn MD, Lowery JJ, Skorput AG, Giuvelis D, Bilsky EJ.","Life Sci. 2010 Apr 10;86(15-16):624-30. doi: 10.1016/j.lfs.2010.02.013. Epub 2010 Feb 14.","Osborn MD","Life Sci","2010","2010/02/18","PMC2848904","NIHMS179398","10.1016/j.lfs.2010.02.013"
"20091529","Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal","Gowing L, Ali R, White JM.","Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD002022. doi: 10.1002/14651858.CD002022.pub3.","Gowing L","Cochrane Database Syst Rev","2010","2010/01/22","PMC7065589","","10.1002/14651858.CD002022.pub3"
"19630726","Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review","Soyka M, Rösner S.","Curr Drug Abuse Rev. 2008 Nov;1(3):280-91. doi: 10.2174/1874473710801030280.","Soyka M","Curr Drug Abuse Rev","2008","2009/07/28","","","10.2174/1874473710801030280"
"19200607","The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study","Kim SW, Grant JE, Potenza MN, Blanco C, Hollander E.","Psychiatry Res. 2009 Mar 31;166(1):76-84. doi: 10.1016/j.psychres.2007.11.008. Epub 2009 Feb 5.","Kim SW","Psychiatry Res","2009","2009/02/10","PMC3641525","NIHMS102281","10.1016/j.psychres.2007.11.008"
"18971181","[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]","Liao RF, Zeng ZP, Wen YG.","Nan Fang Yi Ke Da Xue Xue Bao. 2008 Oct;28(10):1816-9.","Liao RF","Nan Fang Yi Ke Da Xue Xue Bao","2008","2008/10/31","","",""
"18581096","Predicting response to opiate antagonists and placebo in the treatment of pathological gambling","Grant JE, Kim SW, Hollander E, Potenza MN.","Psychopharmacology (Berl). 2008 Nov;200(4):521-7. doi: 10.1007/s00213-008-1235-3. Epub 2008 Jun 26.","Grant JE","Psychopharmacology (Berl)","2008","2008/06/27","PMC3683409","NIHMS199198","10.1007/s00213-008-1235-3"
"18537939","Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers","Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Mäkelä R, Kranzler HR.","Alcohol Clin Exp Res. 2008 Jul;32(7):1159-66. doi: 10.1111/j.1530-0277.2008.00735.x.","Arias AJ","Alcohol Clin Exp Res","2008","2008/06/10","PMC2950972","NIHMS238559","10.1111/j.1530-0277.2008.00735.x"
"18428571","Preclinical models to evaluate potential pharmacotherapeutic agents in treating alcoholism and studying the neuropharmacological bases of ethanol-seeking behaviors in rats","June HL.","Curr Protoc Neurosci. 2002 Aug;Chapter 9:Unit 9.12. doi: 10.1002/0471142301.ns0912s19.","June HL","Curr Protoc Neurosci","2002","2008/04/23","","","10.1002/0471142301.ns0912s19"
"17684846","Plasma met-enkephalin, beta-endorphin and leu-enkephalin levels in human hepatic encephalopathy","Kamel L, Saleh A, Morsy A, Ghali A, El Khayat H.","East Mediterr Health J. 2007 Mar-Apr;13(2):257-65.","Kamel L","East Mediterr Health J","2007","2007/08/10","","",""
"17473837","Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence","Walker BM, Koob GF.","Neuropsychopharmacology. 2008 Feb;33(3):643-52. doi: 10.1038/sj.npp.1301438. Epub 2007 May 2.","Walker BM","Neuropsychopharmacology","2008","2007/05/03","PMC2739278","NIHMS140624","10.1038/sj.npp.1301438"
"17451401","Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study","Karhuvaara S, Simojoki K, Virta A, Rosberg M, Löyttyniemi E, Nurminen T, Kallio A, Mäkelä R.","Alcohol Clin Exp Res. 2007 Jul;31(7):1179-87. doi: 10.1111/j.1530-0277.2007.00401.x. Epub 2007 Apr 19.","Karhuvaara S","Alcohol Clin Exp Res","2007","2007/04/25","","","10.1111/j.1530-0277.2007.00401.x"
"17443124","Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food","Cottone P, Sabino V, Steardo L, Zorrilla EP.","Neuropsychopharmacology. 2008 Feb;33(3):524-35. doi: 10.1038/sj.npp.1301430. Epub 2007 Apr 18.","Cottone P","Neuropsychopharmacology","2008","2007/04/20","","","10.1038/sj.npp.1301430"
"17329173","Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans","Li P, Chen X, Dai X, Wen A, Zhang Y, Zhong D.","J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):479-84. doi: 10.1016/j.jchromb.2007.02.013. Epub 2007 Feb 15.","Li P","J Chromatogr B Analyt Technol Biomed Life Sci","2007","2007/03/03","","","10.1016/j.jchromb.2007.02.013"
"17139110","The permeation of nalmefene hydrochloride across different regions of ovine nasal mucosa","Du G, Gao Y, Nie S, Pan W.","Chem Pharm Bull (Tokyo). 2006 Dec;54(12):1722-4. doi: 10.1248/cpb.54.1722.","Du G","Chem Pharm Bull (Tokyo)","2006","2006/12/02","","","10.1248/cpb.54.1722"
"17060493","Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans","Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, Kreek MJ.","J Pharmacol Exp Ther. 2007 Jan;320(1):300-6. doi: 10.1124/jpet.106.112417. Epub 2006 Oct 23.","Butelman ER","J Pharmacol Exp Ther","2007","2006/10/25","","","10.1124/jpet.106.112417"
"16819215","Optimization of the preparation of nalmefene-loaded sustained-release microspheres using central composite design","Wu XG, Li G, Gao YL.","Chem Pharm Bull (Tokyo). 2006 Jul;54(7):977-81. doi: 10.1248/cpb.54.977.","Wu XG","Chem Pharm Bull (Tokyo)","2006","2006/07/05","","","10.1248/cpb.54.977"
"16449486","Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A.","Am J Psychiatry. 2006 Feb;163(2):303-12. doi: 10.1176/appi.ajp.163.2.303.","Grant JE","Am J Psychiatry","2006","2006/02/02","","","10.1176/appi.ajp.163.2.303"
"16449466","Pathological gambling: focusing on the addiction, not the activity","Tamminga CA, Nestler EJ.","Am J Psychiatry. 2006 Feb;163(2):180-1. doi: 10.1176/appi.ajp.163.2.180.","Tamminga CA","Am J Psychiatry","2006","2006/02/02","","","10.1176/appi.ajp.163.2.180"
"16422967","Pharmacotherapy for erectile dysfunction","Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, Carson C, Corbin J, Francis S, DeBusk R, Eardley I, Hedlund H, Hutter A, Jackson G, Kloner R, Lin CS, McVary K, McCullough A, Nehra A, Porst H, Schulman C, Seftel A, Sharlip I, Stief C, Teloken C.","J Sex Med. 2004 Sep;1(2):128-40. doi: 10.1111/j.1743-6109.2004.04021.x.","Padma-Nathan H","J Sex Med","2004","2006/01/21","","","10.1111/j.1743-6109.2004.04021.x"
"16379031","Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene","Geer EB, Landman RE, Wardlaw SL, Conwell IM, Freda PU.","Pituitary. 2005;8(2):115-22. doi: 10.1007/s11102-005-5227-6.","Geer EB","Pituitary","2005","2005/12/28","","","10.1007/s11102-005-5227-6"
"16001107","Unexpected placebo response in premenstrual dysphoric disorder: implication of endogenous opioids","Van Ree JM, Schagen Van Leeuwen JH, Koppeschaar HP, Te Velde ER.","Psychopharmacology (Berl). 2005 Oct;182(2):318-9. doi: 10.1007/s00213-005-0090-8. Epub 2005 Oct 19.","Van Ree JM","Psychopharmacology (Berl)","2005","2005/07/08","","","10.1007/s00213-005-0090-8"
"15988468","Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?","Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ.","Neuropsychopharmacology. 2005 Dec;30(12):2254-62. doi: 10.1038/sj.npp.1300811.","Bart G","Neuropsychopharmacology","2005","2005/07/01","","","10.1038/sj.npp.1300811"
"15956985","Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing","Ingman K, Hagelberg N, Aalto S, Någren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hietala J, Scheinin H.","Neuropsychopharmacology. 2005 Dec;30(12):2245-53. doi: 10.1038/sj.npp.1300790.","Ingman K","Neuropsychopharmacology","2005","2005/06/16","","","10.1038/sj.npp.1300790"
"15842759","Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry","Fang WB, Andrenyak DM, Moody DE, Nuwayser ES.","J Anal Toxicol. 2005 Apr;29(3):169-74. doi: 10.1093/jat/29.3.169.","Fang WB","J Anal Toxicol","2005","2005/04/22","","","10.1093/jat/29.3.169"
"15674887","Opioid antagonists for alcohol dependence","Srisurapanont M, Jarusuraisin N.","Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001867. doi: 10.1002/14651858.CD001867.pub2.","Srisurapanont M","Cochrane Database Syst Rev","2005","2005/01/28","","","10.1002/14651858.CD001867.pub2"
"15365307","Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers","Drobes DJ, Anton RF, Thomas SE, Voronin K.","Alcohol Clin Exp Res. 2004 Sep;28(9):1362-70. doi: 10.1097/01.alc.0000139704.88862.01.","Drobes DJ","Alcohol Clin Exp Res","2004","2004/09/15","","","10.1097/01.alc.0000139704.88862.01"
"15363499","Implantable technology for long-term delivery of nalmefene for treatment of alcoholism","Costantini LC, Kleppner SR, McDonough J, Azar MR, Patel R.","Int J Pharm. 2004 Sep 28;283(1-2):35-44. doi: 10.1016/j.ijpharm.2004.05.034.","Costantini LC","Int J Pharm","2004","2004/09/15","","","10.1016/j.ijpharm.2004.05.034"
"15232334","A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence","Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S.","J Clin Psychopharmacol. 2004 Aug;24(4):421-8. doi: 10.1097/01.jcp.0000130555.63254.73.","Anton RF","J Clin Psychopharmacol","2004","2004/07/03","","","10.1097/01.jcp.0000130555.63254.73"
"15219821","Chronic administration of nalmefene leads to increased food intake and body weight gain in mice","Chen RZ, Huang RR, Shen CP, MacNeil DJ, Fong TM.","Eur J Pharmacol. 2004 Jul 8;495(1):63-6. doi: 10.1016/j.ejphar.2004.05.025.","Chen RZ","Eur J Pharmacol","2004","2004/06/29","","","10.1016/j.ejphar.2004.05.025"
"14870516","[Drug therapy of alcohol dependence--a critical review]","Salaspuro M.","Duodecim. 2003;119(24):2503-7.","Salaspuro M","Duodecim","2003","2004/02/12","","",""
"14759503","Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice","Chen RZ, Huang RR, Shen CP, MacNeil DJ, Fong TM.","Brain Res. 2004 Mar 5;999(2):227-30. doi: 10.1016/j.brainres.2003.12.004.","Chen RZ","Brain Res","2004","2004/02/05","","","10.1016/j.brainres.2003.12.004"
"14603266","Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats","June HL, Cummings R, Eiler WJ 2nd, Foster KL, McKay PF, Seyoum R, Garcia M, McCane S, Grey C, Hawkins SE, Mason D.","Neuropsychopharmacology. 2004 Feb;29(2):285-99. doi: 10.1038/sj.npp.1300338.","June HL","Neuropsychopharmacology","2004","2003/11/07","","","10.1038/sj.npp.1300338"
"14557717","Characterization of scratching responses in rats following centrally administered morphine or bombesin","Lee H, Naughton NN, Woods JH, Ko MC.","Behav Pharmacol. 2003 Nov;14(7):501-8. doi: 10.1097/01.fbp.0000095082.80017.0f.","Lee H","Behav Pharmacol","2003","2003/10/15","PMC1810379","NIHMS18489","10.1097/01.fbp.0000095082.80017.0f"
"12655322","A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene","Drobes DJ, Anton RF, Thomas SE, Voronin K.","Neuropsychopharmacology. 2003 Apr;28(4):755-64. doi: 10.1038/sj.npp.1300101. Epub 2002 Oct 30.","Drobes DJ","Neuropsychopharmacology","2003","2003/03/26","","","10.1038/sj.npp.1300101"
"12062477","Potentiation of the excitatory action of NMDA in ventrolateral periaqueductal gray by the mu-opioid receptor agonist, DAMGO","Kow LM, Commons KG, Ogawa S, Pfaff DW.","Brain Res. 2002 May 10;935(1-2):87-102. doi: 10.1016/s0006-8993(02)02532-5.","Kow LM","Brain Res","2002","2002/06/14","","","10.1016/s0006-8993(02)02532-5"
"12038658","Neuroprotective agents in acute ischemic stroke","Sareen D.","J Assoc Physicians India. 2002 Feb;50:250-8.","Sareen D","J Assoc Physicians India","2002","2002/06/01","","",""
"12031840","Rapid and sensitive determination of nalmefene in human plasma by gas chromatography-mass spectrometry","Xie S, Suckow RF, Mason BJ, Allen D, Cooper TB.","J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25;773(2):143-9. doi: 10.1016/s1570-0232(02)00138-1.","Xie S","J Chromatogr B Analyt Technol Biomed Life Sci","2002","2002/05/29","","","10.1016/s1570-0232(02)00138-1"
"11887546","The use of nalmefene for intrathecal opioid-associated nausea in postpartum patients","Ward RC, Lawrence RL, Hawkins RJ, DiChiara SE, Biegner AR, Vacchiano CA.","AANA J. 2002 Feb;70(1):57-60.","Ward RC","AANA J","2002","2002/03/13","","",""
"11759562","The impact of nalmefene on side effects due to intrathecal morphine at cesarean section","Pellegrini JE, Bailey SL, Graves J, Paice JA, Shott S, Faut-Callahan M.","AANA J. 2001 Jun;69(3):199-205.","Pellegrini JE","AANA J","2001","2002/01/05","","",""
"11707162","Opioid antagonists in the treatment of alcohol dependence","O'Leary G, Borrow J, Weiss RD.","Curr Psychiatry Rep. 2001 Dec;3(6):484-8. doi: 10.1007/s11920-001-0042-x.","O'Leary G","Curr Psychiatry Rep","2001","2001/11/15","","","10.1007/s11920-001-0042-x"
"11698998","Nalmefene for elective reversal of procedural sedation in children","Chumpa A, Kaplan RL, Burns MM, Shannon MW.","Am J Emerg Med. 2001 Nov;19(7):545-8. doi: 10.1053/ajem.2001.27141.","Chumpa A","Am J Emerg Med","2001","2001/11/08","","","10.1053/ajem.2001.27141"
"11584870","Pharmacologic approaches to the management of alcoholism","Anton RF.","J Clin Psychiatry. 2001;62 Suppl 20:11-7.","Anton RF","J Clin Psychiatry","2001","2001/10/05","","",""
"11413242","Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence","Wang D, Raehal KM, Bilsky EJ, Sadée W.","J Neurochem. 2001 Jun;77(6):1590-600. doi: 10.1046/j.1471-4159.2001.00362.x.","Wang D","J Neurochem","2001","2001/06/20","","","10.1046/j.1471-4159.2001.00362.x"
"11268820","New developments in the pharmacotherapy of alcohol dependence","Myrick H, Brady KT, Malcolm R.","Am J Addict. 2001;10(s1):s3-s15. doi: 10.1080/10550490150504092.","Myrick H","Am J Addict","2001","2001/03/28","","","10.1080/10550490150504092"
"11146395","Inhibition of passive cutaneous anaphylaxis-associated scratching behavior by mu-opioid receptor antagonists in ICR mice","Inagaki N, Nakamura N, Nagao M, Kawasaki H, Nagai H.","Int Arch Allergy Immunol. 2000 Dec;123(4):365-8. doi: 10.1159/000053650.","Inagaki N","Int Arch Allergy Immunol","2000","2001/01/09","","","10.1159/000053650"
"10908513","Opioid antagonists for alcohol dependence","Srisurapanont M, Jarusuraisin N.","Cochrane Database Syst Rev. 2000;(3):CD001867. doi: 10.1002/14651858.CD001867.","Srisurapanont M","Cochrane Database Syst Rev","2000","2000/07/25","","","10.1002/14651858.CD001867"
"10907964","Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study","Rosen DA, Morris JL, Rosen KR, Nelson ER, Steelman RJ, Gustafson RA, Wilhelm JA, Chang CT, Thackara JW, Frye RF.","Pharmacotherapy. 2000 Jul;20(7):745-9. doi: 10.1592/phco.20.9.745.35207.","Rosen DA","Pharmacotherapy","2000","2000/07/25","","","10.1592/phco.20.9.745.35207"
"10880679","Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys","Mello NK, Mendelson JH, Kelly M.","Pharmacol Biochem Behav. 2000 Jun;66(2):275-83. doi: 10.1016/s0091-3057(00)00190-8.","Mello NK","Pharmacol Biochem Behav","2000","2000/07/06","","","10.1016/s0091-3057(00)00190-8"
"10835438","Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators","Clark WM, Raps EC, Tong DC, Kelly RE.","Stroke. 2000 Jun;31(6):1234-9. doi: 10.1161/01.str.31.6.1234.","Clark WM","Stroke","2000","2000/06/03","","","10.1161/01.str.31.6.1234"
"10821987","Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans","Jones HE, Johnson RE, Fudala PJ, Henningfield JE, Heishman SJ.","Drug Alcohol Depend. 2000 Jul 1;60(1):29-37. doi: 10.1016/s0376-8716(99)00138-6.","Jones HE","Drug Alcohol Depend","2000","2000/05/24","","","10.1016/s0376-8716(99)00138-6"
"10757131","Drinking in alcoholics following an alcohol challenge research protocol","Drobes DJ, Anton RF.","J Stud Alcohol. 2000 Mar;61(2):220-4. doi: 10.15288/jsa.2000.61.220.","Drobes DJ","J Stud Alcohol","2000","2000/04/11","","","10.15288/jsa.2000.61.220"
"10754620","Maximum tolerated dose of nalmefene in patients receiving epidural fentanyl and dilute bupivacaine for postoperative analgesia","Dougherty TB, Porche VH, Thall PF.","Anesthesiology. 2000 Apr;92(4):1010-6. doi: 10.1097/00000542-200004000-00018.","Dougherty TB","Anesthesiology","2000","2001/02/07","","","10.1097/00000542-200004000-00018"
"10719958","An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception","Ko MC, Naughton NN.","Anesthesiology. 2000 Mar;92(3):795-805. doi: 10.1097/00000542-200003000-00023.","Ko MC","Anesthesiology","2000","2000/03/17","PMC1937505","NIHMS26641","10.1097/00000542-200003000-00023"
"10677202","Nalmefene for alcohol dependence","","Harv Ment Health Lett. 2000 Mar;16(9):7.","","Harv Ment Health Lett","2000","2000/02/17","","",""
"10598605","Rapid opioid detoxification during general anesthesia: a review of 20 patients","Gold CG, Cullen DJ, Gonzales S, Houtmeyers D, Dwyer MJ.","Anesthesiology. 1999 Dec;91(6):1639-47. doi: 10.1097/00000542-199912000-00015.","Gold CG","Anesthesiology","1999","1999/12/22","","","10.1097/00000542-199912000-00015"
"10565979","Nalmefene. JF 1, nalmetrene, NIH 10365, ORF 11676, Arthrene, Cervene, Incystene, Revex","","Drugs R D. 1999 Jan;1(1):32-3. doi: 10.2165/00126839-199901010-00012.","","Drugs R D","1999","1999/11/24","","","10.2165/00126839-199901010-00012"
"10459118","Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study","Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA.","J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):431-4. doi: 10.1016/s0190-9622(99)70117-9.","Bergasa NV","J Am Acad Dermatol","1999","1999/08/25","","","10.1016/s0190-9622(99)70117-9"
"10435606","A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB.","Arch Gen Psychiatry. 1999 Aug;56(8):719-24. doi: 10.1001/archpsyc.56.8.719.","Mason BJ","Arch Gen Psychiatry","1999","1999/08/06","","","10.1001/archpsyc.56.8.719"
"10381993","Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose","Kaplan JL, Marx JA, Calabro JJ, Gin-Shaw SL, Spiller JD, Spivey WL, Gaddis GM, Zhao N, Harchelroad FP Jr.","Ann Emerg Med. 1999 Jul;34(1):42-50. doi: 10.1016/s0196-0644(99)70270-2.","Kaplan JL","Ann Emerg Med","1999","1999/06/26","","","10.1016/s0196-0644(99)70270-2"
"10220088","Nalmefene hydrochloride","Chumpa A.","Pediatr Emerg Care. 1999 Apr;15(2):141-3. doi: 10.1097/00006565-199904000-00016.","Chumpa A","Pediatr Emerg Care","1999","1999/04/29","","","10.1097/00006565-199904000-00016"
"10208148","Pharmacological treatment of alcohol dependence: a review of the evidence","Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT.","JAMA. 1999 Apr 14;281(14):1318-25. doi: 10.1001/jama.281.14.1318.","Garbutt JC","JAMA","1999","1999/04/20","","","10.1001/jama.281.14.1318"
"10201671","Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia","Joshi GP, Duffy L, Chehade J, Wesevich J, Gajraj N, Johnson ER.","Anesthesiology. 1999 Apr;90(4):1007-11. doi: 10.1097/00000542-199904000-00013.","Joshi GP","Anesthesiology","1999","1999/04/14","","","10.1097/00000542-199904000-00013"
"9884166","The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats","June HL, Grey C, Warren-Reese C, Durr LF, Ricks-Cord A, Johnson A, McCane S, Williams LS, Mason D, Cummings R, Lawrence A.","Alcohol Clin Exp Res. 1998 Dec;22(9):2174-85.","June HL","Alcohol Clin Exp Res","1998","1999/01/12","","",""
"9862779","Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions","Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A.","J Pharmacol Exp Ther. 1999 Jan;288(1):260-9.","Kreek MJ","J Pharmacol Exp Ther","1999","1998/12/23","","",""
"9832959","Effect of naltrexone and its derivatives, nalmefene and naltrindole, on conditioned anticipatory behaviour and saccharin intake in rats","Chow BL, Sellers EM, Tomkins DM.","Behav Pharmacol. 1997 Dec;8(8):725-35. doi: 10.1097/00008877-199712000-00008.","Chow BL","Behav Pharmacol","1997","1998/12/02","","","10.1097/00008877-199712000-00008"
"9802524","Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism","Schluger JH, Ho A, Borg L, Porter M, Maniar S, Gunduz M, Perret G, King A, Kreek MJ.","Alcohol Clin Exp Res. 1998 Oct;22(7):1430-6. doi: 10.1111/j.1530-0277.1998.tb03931.x.","Schluger JH","Alcohol Clin Exp Res","1998","1998/11/05","","","10.1111/j.1530-0277.1998.tb03931.x"
"9797933","Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions","Mills IH, Park GR, Manara AR, Merriman RJ.","QJM. 1998 Jul;91(7):493-503. doi: 10.1093/qjmed/91.7.493.","Mills IH","QJM","1998","1998/11/03","","","10.1093/qjmed/91.7.493"
"9783840","New treatment options for substance abuse from a public health viewpoint","Sinclair JD.","Ann Med. 1998 Aug;30(4):406-11. doi: 10.3109/07853899809029941.","Sinclair JD","Ann Med","1998","1998/10/23","","","10.3109/07853899809029941"
"9610980","Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine","Wang DS, Sternbach G, Varon J.","J Emerg Med. 1998 May-Jun;16(3):471-5. doi: 10.1016/s0736-4679(98)00019-5.","Wang DS","J Emerg Med","1998","1998/06/04","","","10.1016/s0736-4679(98)00019-5"
"9590665","Opioid antagonists in the treatment of impulse-control disorders","Kim SW.","J Clin Psychiatry. 1998 Apr;59(4):159-64.","Kim SW","J Clin Psychiatry","1998","1998/05/20","","",""
"9500694","Open-label trial of oral nalmefene therapy for the pruritus of cholestasis","Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA.","Hepatology. 1998 Mar;27(3):679-84. doi: 10.1002/hep.510270307.","Bergasa NV","Hepatology","1998","1998/03/21","","","10.1002/hep.510270307"
"9475374","Effects of nalmefene, CG3703, tirilazad, or dopamine on cerebral blood flow, oxygen delivery, and electroencephalographic activity after traumatic brain injury and hemorrhage","Dewitt DS, Prough DS, Uchida T, Deal DD, Vines SM.","J Neurotrauma. 1997 Dec;14(12):931-41. doi: 10.1089/neu.1997.14.931.","Dewitt DS","J Neurotrauma","1997","1998/02/25","","","10.1089/neu.1997.14.931"
"9474037","Nalmefene and the urine opiate screen","Storrow AB, Hernandez AV, Norton JA.","Clin Chem. 1998 Feb;44(2):346-8.","Storrow AB","Clin Chem","1998","1998/02/25","","",""
"9439841","Use of positron emission tomography to measure the effects of nalmefene on D1 and D2 dopamine receptors in rat brain","Unterwald EM, Tsukada H, Kakiuchi T, Kosugi T, Nishiyama S, Kreek MJ.","Brain Res. 1997 Nov 14;775(1-2):183-8. doi: 10.1016/s0006-8993(97)00931-1.","Unterwald EM","Brain Res","1997","1998/01/24","","","10.1016/s0006-8993(97)00931-1"
"9374341","Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system","Kim S, Wagner HN Jr, Villemagne VL, Kao PF, Dannals RF, Ravert HT, Joh T, Dixon RB, Civelek AC.","J Nucl Med. 1997 Nov;38(11):1726-31.","Kim S","J Nucl Med","1997","1997/11/28","","",""
"9168225","Nalmefene, an intravenous alternative to naltrexone for extradural morphine prophylaxis","Stuart AL, McDavid AJ.","Reg Anesth. 1997 May-Jun;22(3):291. doi: 10.1016/s1098-7339(06)80018-0.","Stuart AL","Reg Anesth","1997","1997/05/01","","","10.1016/s1098-7339(06)80018-0"
"9024170","Effects of liver disease on the disposition of the opioid antagonist nalmefene","Frye RF, Matzke GR, Schade R, Dixon R, Rabinovitz M.","Clin Pharmacol Ther. 1997 Jan;61(1):15-23. doi: 10.1016/S0009-9236(97)90178-8.","Frye RF","Clin Pharmacol Ther","1997","1997/01/01","","","10.1016/S0009-9236(97)90178-8"
"8998112","Potential danger of nalmefene use in the emergency department","Gaeta TJ, Capodano RJ, Spevack TA.","Ann Emerg Med. 1997 Jan;29(1):193-4. doi: 10.1016/s0196-0644(97)70334-2.","Gaeta TJ","Ann Emerg Med","1997","1997/01/01","","","10.1016/s0196-0644(97)70334-2"
"8989029","Acute pulmonary edema in a young male after intravenous nalmefene","Henderson CA, Reynolds JE.","Anesth Analg. 1997 Jan;84(1):218-9. doi: 10.1097/00000539-199701000-00040.","Henderson CA","Anesth Analg","1997","1997/01/01","","","10.1097/00000539-199701000-00040"
"8947268","International update: new findings on promising medications","Litten RZ.","Alcohol Clin Exp Res. 1996 Nov;20(8 Suppl):216A-218A. doi: 10.1111/j.1530-0277.1996.tb01779.x.","Litten RZ","Alcohol Clin Exp Res","1996","1996/11/01","","","10.1111/j.1530-0277.1996.tb01779.x"
"8933423","Stability of revex, nalmefene hydrochloride injection, in injectable solutions","Murthy SS, Brittain HG.","J Pharm Biomed Anal. 1996 Nov;15(2):221-6. doi: 10.1016/0731-7085(96)01847-x.","Murthy SS","J Pharm Biomed Anal","1996","1996/11/01","","","10.1016/0731-7085(96)01847-x"
"8904989","Dosing issues in the pharmacotherapy of alcoholism","Mason BJ.","Alcohol Clin Exp Res. 1996 Oct;20(7 Suppl):10A-16A. doi: 10.1111/j.1530-0277.1996.tb01184.x.","Mason BJ","Alcohol Clin Exp Res","1996","1996/10/01","","","10.1111/j.1530-0277.1996.tb01184.x"
"8877019","The effect of age on the pharmacokinetics of the opioid antagonist nalmefene","Frye RF, Matzke GR, Jallad NS, Wilhelm JA, Bikhazi GB.","Br J Clin Pharmacol. 1996 Sep;42(3):301-6. doi: 10.1046/j.1365-2125.1996.04133.x.","Frye RF","Br J Clin Pharmacol","1996","1996/09/01","PMC2042672","","10.1046/j.1365-2125.1996.04133.x"
"8852390","The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene","Matzke GR, Frye RF, Alexander AC, Reynolds R, Dixon R, Johnston J, Rault RM.","J Clin Pharmacol. 1996 Feb;36(2):144-51. doi: 10.1002/j.1552-4604.1996.tb04179.x.","Matzke GR","J Clin Pharmacol","1996","1996/02/01","","","10.1002/j.1552-4604.1996.tb04179.x"
"8846056","Stability of Revex, nalmefene hydrochloride injection","Brittain HG, Lafferty L, Bousserski P, Diegnan G, Lessor R, Small C, Pejaver S.","PDA J Pharm Sci Technol. 1996 Jan-Feb;50(1):35-9.","Brittain HG","PDA J Pharm Sci Technol","1996","1996/01/01","","",""
"8819305","Disposition of the opioid antagonist, nalmefene, in rat and dog","Murthy SS, Mathur C, Kvalo LT, Lessor RA, Wilhelm JA.","Xenobiotica. 1996 Jul;26(7):779-92. doi: 10.3109/00498259609046748.","Murthy SS","Xenobiotica","1996","1996/07/01","","","10.3109/00498259609046748"
"8778169","Effects of melatonin in vivo upon luteinizing hormone and prolactin releases induced by opiate receptor antagonists in adult male rats","Shacoori V, Saïag B, Lemay V, Girre A, Rault B.","J Endocrinol Invest. 1996 Feb;19(2):76-82. doi: 10.1007/BF03349840.","Shacoori V","J Endocrinol Invest","1996","1996/02/01","","","10.1007/BF03349840"
"8574503","Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation","Wilhelm JA, Veng-Pedersen P, Zakszewski TB, Osifchin E, Waters SJ.","Int J Clin Pharmacol Ther. 1995 Oct;33(10):540-5.","Wilhelm JA","Int J Clin Pharmacol Ther","1995","1995/10/01","","",""
"8565795","Current strategies for the treatment of alcohol dependence in the United States","O'Malley SS.","Drug Alcohol Depend. 1995 Sep;39 Suppl 1:S3-7. doi: 10.1016/0376-8716(95)01167-w.","O'Malley SS","Drug Alcohol Depend","1995","1995/09/01","","","10.1016/0376-8716(95)01167-w"
"8537889","Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparison","Veng-Pedersen P, Wilhelm JA, Zakszewski TB, Osifchin E, Waters SJ.","J Pharm Sci. 1995 Sep;84(9):1101-6. doi: 10.1002/jps.2600840913.","Veng-Pedersen P","J Pharm Sci","1995","1995/09/01","","","10.1002/jps.2600840913"
"8529534","Assessment of nalmefene glucuronide as a selective gut opioid antagonist","Cheskin LJ, Chami TN, Johnson RE, Jaffe JH.","Drug Alcohol Depend. 1995 Aug;39(2):151-4. doi: 10.1016/0376-8716(95)01153-p.","Cheskin LJ","Drug Alcohol Depend","1995","1995/08/01","","","10.1016/0376-8716(95)01153-p"
"8498150","Nalmefene enhances LH secretion in a proportion of oligo-amenorrheic athletes","McArthur JW, Turnbull BA, Pehrson J, Bauman M, Henley K, Turner A, Evans WJ, Bullen BA, Skrinar GS.","Acta Endocrinol (Copenh). 1993 Apr;128(4):325-33. doi: 10.1530/acta.0.1280325.","McArthur JW","Acta Endocrinol (Copenh)","1993","1993/04/01","","","10.1530/acta.0.1280325"
"8491826","Determination of nalmefene in plasma by high-performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies","Chou JZ, Albeck H, Kreek MJ.","J Chromatogr. 1993 Apr 2;613(2):359-64. doi: 10.1016/0378-4347(93)80155-w.","Chou JZ","J Chromatogr","1993","1993/04/02","","","10.1016/0378-4347(93)80155-w"
"8472282","Influence of hyperkalaemia and ischaemia on non-receptor-mediated cardiac electrophysiological effects of naloxone","Oldroyd KG, Hicks MN, Cobbe SM.","Cardiovasc Res. 1993 Feb;27(2):296-303. doi: 10.1093/cvr/27.2.296.","Oldroyd KG","Cardiovasc Res","1993","1993/02/01","","","10.1093/cvr/27.2.296"
"8450619","[Prevention of undesirable effects during the use of opiate antagonists]","Rust M.","Klin Anasthesiol Intensivther. 1993;42:108-16.","Rust M","Klin Anasthesiol Intensivther","1993","1993/01/01","","",""
"8432363","A comparison of YM-14673, U-50488H, and nalmefene after spinal cord injury in the rat","Behrmann DL, Bresnahan JC, Beattie MS.","Exp Neurol. 1993 Feb;119(2):258-67. doi: 10.1006/exnr.1993.1028.","Behrmann DL","Exp Neurol","1993","1993/02/01","","","10.1006/exnr.1993.1028"
"8427429","Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study","Kaplan JL, Marx JA.","Ann Emerg Med. 1993 Feb;22(2):187-90. doi: 10.1016/s0196-0644(05)80200-8.","Kaplan JL","Ann Emerg Med","1993","1993/02/01","","","10.1016/s0196-0644(05)80200-8"
"8411221","Comparison of single and combination drug treatment strategies in experimental brain trauma","Faden AI.","J Neurotrauma. 1993 Summer;10(2):91-100. doi: 10.1089/neu.1993.10.91.","Faden AI","J Neurotrauma","1993","1993/01/01","","","10.1089/neu.1993.10.91"
"8300813","The effect of nalmefene on pulsatile secretion of luteinizing hormone and prolactin in men","Graves GR, Kennedy TG, Weick RF, Casper RF.","Hum Reprod. 1993 Oct;8(10):1598-603. doi: 10.1093/oxfordjournals.humrep.a137898.","Graves GR","Hum Reprod","1993","1993/10/01","","","10.1093/oxfordjournals.humrep.a137898"
"8284832","Nalmefene in the treatment of interstitial cystitis","Stone NN.","Urol Clin North Am. 1994 Feb;21(1):101-6.","Stone NN","Urol Clin North Am","1994","1994/02/01","","",""
"8163362","A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder","Glover H.","Isr J Psychiatry Relat Sci. 1993;30(4):255-63.","Glover H","Isr J Psychiatry Relat Sci","1993","1993/01/01","","",""
"8109774","Comparison of potency and duration of action of nalmefene and naloxone","Glass PS, Jhaveri RM, Smith LR.","Anesth Analg. 1994 Mar;78(3):536-41. doi: 10.1213/00000539-199403000-00021.","Glass PS","Anesth Analg","1994","1994/03/01","","","10.1213/00000539-199403000-00021"
"8105790","Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients","Rapaport MH, Wolkowitz O, Kelsoe JR, Pato C, Konicki PE, Pickar D.","Neuropsychopharmacology. 1993 Sep;9(2):111-5. doi: 10.1038/npp.1993.49.","Rapaport MH","Neuropsychopharmacology","1993","1993/09/01","","","10.1038/npp.1993.49"
"7932212","Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys","France CP, Gerak LR.","J Pharmacol Exp Ther. 1994 Sep;270(3):992-9.","France CP","J Pharmacol Exp Ther","1994","1994/09/01","","",""
"7908601","Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia","Graham SH, Shimizu H, Newman A, Weinstein P, Faden AI.","Brain Res. 1993 Dec 31;632(1-2):346-50. doi: 10.1016/0006-8993(93)91175-r.","Graham SH","Brain Res","1993","1993/12/31","","","10.1016/0006-8993(93)91175-r"
"7902680","Inhibiting a spinal dynorphin A component enhances intrathecal morphine antinociception in mice","Holmes BB, Fujimoto JM.","Anesth Analg. 1993 Dec;77(6):1166-73. doi: 10.1213/00000539-199312000-00015.","Holmes BB","Anesth Analg","1993","1993/12/01","","","10.1213/00000539-199312000-00015"
"7847604","Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject","Salvato FR, Mason BJ.","Alcohol Clin Exp Res. 1994 Oct;18(5):1187-9. doi: 10.1111/j.1530-0277.1994.tb00102.x.","Salvato FR","Alcohol Clin Exp Res","1994","1994/10/01","","","10.1111/j.1530-0277.1994.tb00102.x"
"7847600","A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence","Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E.","Alcohol Clin Exp Res. 1994 Oct;18(5):1162-7. doi: 10.1111/j.1530-0277.1994.tb00098.x.","Mason BJ","Alcohol Clin Exp Res","1994","1994/10/01","","","10.1111/j.1530-0277.1994.tb00098.x"
"7588425","Melatonin modifies prolactin release induced by opiate antagonists in male rats","Shacoori V, Saiag B, Rault B.","Endocr Res. 1995 Aug;21(3):545-53. doi: 10.1080/07435809509030472.","Shacoori V","Endocr Res","1995","1995/08/01","","","10.1080/07435809509030472"
"7565300","Nalmefene--a long-acting injectable opioid antagonist","","Med Lett Drugs Ther. 1995 Oct 27;37(960):97-8.","","Med Lett Drugs Ther","1995","1995/10/27","","",""
"7475895","Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig","Culpepper-Morgan JA, Holt PR, LaRoche D, Kreek MJ.","Life Sci. 1995;56(14):1187-92. doi: 10.1016/0024-3205(95)00057-d.","Culpepper-Morgan JA","Life Sci","1995","1995/01/01","","","10.1016/0024-3205(95)00057-d"
"6665302","Nalmefene: quantitation of a new narcotic antagonist in human plasma using high performance-liquid chromatography with electrochemical detection","Hsiao J, Dixon R.","Res Commun Chem Pathol Pharmacol. 1983 Dec;42(3):449-54.","Hsiao J","Res Commun Chem Pathol Pharmacol","1983","1983/12/01","","",""
"6634872","Nalmefene decreases meal size, food and water intake and weight gain in Zucker rats","McLaughlin CL, Baile CA.","Pharmacol Biochem Behav. 1983 Aug;19(2):235-40. doi: 10.1016/0091-3057(83)90045-x.","McLaughlin CL","Pharmacol Biochem Behav","1983","1983/08/01","","","10.1016/0091-3057(83)90045-x"
"6541122","Do testicular opiates regulate Leydig cell function?","Gerendai I, Shaha C, Thau R, Bardin CW.","Endocrinology. 1984 Oct;115(4):1645-7. doi: 10.1210/endo-115-4-1645.","Gerendai I","Endocrinology","1984","1984/10/01","","","10.1210/endo-115-4-1645"
"6540897","A rapid, quantitative in vivo assay for narcotic antagonists","Katovich MJ, Simpkins JW, Song IC, Bodor N, Tuttle R.","Subst Alcohol Actions Misuse. 1984;5(2):87-95.","Katovich MJ","Subst Alcohol Actions Misuse","1984","1984/01/01","","",""
"6520774","Nalmefene: radioimmunoassay for a new opioid antagonist","Dixon R, Hsiao J, Taaffe W, Hahn E, Tuttle R.","J Pharm Sci. 1984 Nov;73(11):1645-6. doi: 10.1002/jps.2600731141.","Dixon R","J Pharm Sci","1984","1984/11/01","","","10.1002/jps.2600731141"
"4059587","Effect of oral nalmefene, an opiate-receptor antagonist, on meal-stimulated gastric acid secretion and serum gastrin concentration in man","Feldman M, Moore L, Walsh JH.","Regul Pept. 1985 Jul;11(3):245-50. doi: 10.1016/0167-0115(85)90056-4.","Feldman M","Regul Pept","1985","1985/07/01","","","10.1016/0167-0115(85)90056-4"
"3946804","Prolonged antagonism of opioid action with intravenous nalmefene in man","Gal TJ, DiFazio CA.","Anesthesiology. 1986 Feb;64(2):175-80. doi: 10.1097/00000542-198602000-00008.","Gal TJ","Anesthesiology","1986","1986/02/01","","","10.1097/00000542-198602000-00008"
"3943269","Nalmefene: intravenous safety and kinetics of a new opioid antagonist","Dixon R, Howes J, Gentile J, Hsu HB, Hsiao J, Garg D, Weidler D, Meyer M, Tuttle R.","Clin Pharmacol Ther. 1986 Jan;39(1):49-53. doi: 10.1038/clpt.1986.9.","Dixon R","Clin Pharmacol Ther","1986","1986/01/01","","","10.1038/clpt.1986.9"
"3842024","Unexpected effects of nalmefene, a new opiate antagonist, on the hypothalamic-pituitary-gonadal axis in the male rat","Limonta P, Bardin CW, Hahn EF, Thau RB.","Steroids. 1985 Dec;46(6):955-65. doi: 10.1016/s0039-128x(85)80003-9.","Limonta P","Steroids","1985","1985/12/01","","","10.1016/s0039-128x(85)80003-9"
"3826875","Investigation into the use of narcotic antagonists in the treatment of a stereotypic behavior pattern (crib-biting) in the horse","Dodman NH, Shuster L, Court MH, Dixon R.","Am J Vet Res. 1987 Feb;48(2):311-9.","Dodman NH","Am J Vet Res","1987","1987/02/01","","",""
"3698906","The effects of opioid receptor antagonists suggest that testicular opiates regulate Sertoli and Leydig cell function in the neonatal rat","Gerendai I, Shaha C, Gunsalus GL, Bardin CW.","Endocrinology. 1986 May;118(5):2039-44. doi: 10.1210/endo-118-5-2039.","Gerendai I","Endocrinology","1986","1986/05/01","","","10.1210/endo-118-5-2039"
"3682088","Immobilization of white-tailed deer by etorphine and xylazine and its antagonism by nalmefene and yohimbine","Kreeger TJ, Plotka ED, Seal US.","J Wildl Dis. 1987 Oct;23(4):619-24. doi: 10.7589/0090-3558-23.4.619.","Kreeger TJ","J Wildl Dis","1987","1987/10/01","","","10.7589/0090-3558-23.4.619"
"3680614","A panic attack precipitated by opiate blockade--a case study","Luby ED, Marrazzi MA.","J Clin Psychopharmacol. 1987 Oct;7(5):361-2. doi: 10.1097/00004714-198710000-00025.","Luby ED","J Clin Psychopharmacol","1987","1987/10/01","","","10.1097/00004714-198710000-00025"
"3680580","Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist","Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, Weidler D.","J Clin Pharmacol. 1987 Mar;27(3):233-9. doi: 10.1002/j.1552-4604.1987.tb02191.x.","Dixon R","J Clin Pharmacol","1987","1987/03/01","","","10.1002/j.1552-4604.1987.tb02191.x"
"3676787","Antagonism of endogenous opioids modulates memory processing","Flood JF, Cherkin A, Morley JE.","Brain Res. 1987 Oct 6;422(2):218-34. doi: 10.1016/0006-8993(87)90929-2.","Flood JF","Brain Res","1987","1987/10/06","","","10.1016/0006-8993(87)90929-2"
"3671362","Antagonism by nalmefene of systemic and intrathecal morphine-induced analgesia in mice","Roerig SC, Arteau C, Fujimoto JM.","Proc Soc Exp Biol Med. 1987 Nov;186(2):234-9. doi: 10.3181/00379727-186-42609.","Roerig SC","Proc Soc Exp Biol Med","1987","1987/11/01","","","10.3181/00379727-186-42609"
"3548443","Failure of nalmefene and estrogen to improve memory in Alzheimer's disease","Weiss BL.","Am J Psychiatry. 1987 Mar;144(3):386-7. doi: 10.1176/ajp.144.3.aj1443386.","Weiss BL","Am J Psychiatry","1987","1987/03/01","","","10.1176/ajp.144.3.aj1443386"
"3539980","Reduction of hyperinsulinemia and insulin resistance by opiate receptor blockade in the polycystic ovary syndrome with acanthosis nigricans","Givens JR, Kurtz BR, Kitabchi AE, Bittle JB, Karas JG, Mitchell JA, Howes JF.","J Clin Endocrinol Metab. 1987 Feb;64(2):377-82. doi: 10.1210/jcem-64-2-377.","Givens JR","J Clin Endocrinol Metab","1987","1987/02/01","","","10.1210/jcem-64-2-377"
"3533370","Prolonged blockade of opioid effect with oral nalmefene","Gal TJ, DiFazio CA, Dixon R.","Clin Pharmacol Ther. 1986 Nov;40(5):537-42. doi: 10.1038/clpt.1986.220.","Gal TJ","Clin Pharmacol Ther","1986","1986/11/01","","","10.1038/clpt.1986.220"
"3410777","Use of a narcotic antagonist (nalmefene) to suppress self-mutilative behavior in a stallion","Dodman NH, Shuster L, Court MH, Patel J.","J Am Vet Med Assoc. 1988 Jun 1;192(11):1585-6.","Dodman NH","J Am Vet Med Assoc","1988","1988/06/01","","",""
"3379356","Induction of LH hypersecretion in cyclic rats during the afternoon of oestrus by oestrogen in conjunction with progesterone antagonism or opioidergic blockade","Lustig RH, Pfaff DW, Fishman J.","J Endocrinol. 1988 May;117(2):229-35. doi: 10.1677/joe.0.1170229.","Lustig RH","J Endocrinol","1988","1988/05/01","","","10.1677/joe.0.1170229"
"3370463","Regional brain glucose uptake in genetically diabetic C57BL/KsJ mice: modulation by the opiate antagonist, nalmefene","Garris DR, Michel ME.","Brain Res. 1988 Apr 5;445(2):262-7. doi: 10.1016/0006-8993(88)91188-2.","Garris DR","Brain Res","1988","1988/04/05","","","10.1016/0006-8993(88)91188-2"
"3367315","Opiate-receptor antagonist nalmefene improves neurological recovery after traumatic spinal cord injury in rats through a central mechanism","Faden AI, Sacksen I, Noble LJ.","J Pharmacol Exp Ther. 1988 May;245(2):742-8.","Faden AI","J Pharmacol Exp Ther","1988","1988/05/01","","",""
"3362942","Effect of morphine and nalmefene on energy balance in diabetic and non-diabetic rats","Levine AS, Grace M, Billington CJ, Gosnell BA, Krahn DD, Brown DM, Morley JE.","Pharmacol Biochem Behav. 1988 Mar;29(3):495-500. doi: 10.1016/0091-3057(88)90010-x.","Levine AS","Pharmacol Biochem Behav","1988","1988/03/01","","","10.1016/0091-3057(88)90010-x"
"3339293","Opioidergic modulation of the oestradiol-induced LH surge in the rat: roles of ovarian steroids","Lustig RH, Pfaff DW, Fishman J.","J Endocrinol. 1988 Jan;116(1):55-69. doi: 10.1677/joe.0.1160055.","Lustig RH","J Endocrinol","1988","1988/01/01","","","10.1677/joe.0.1160055"
"3335997","Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates","Simpkins JW, Smulkowski M, Dixon R, Tuttle R.","J Pharmacol Exp Ther. 1988 Jan;244(1):195-205.","Simpkins JW","J Pharmacol Exp Ther","1988","1988/01/01","","",""
"3204249","The effects of nalmefene, a potent oral opiate antagonist, on exercise-induced bronchospasm","Christopher MA, Wyzan D, Harman E, Hendeles L.","J Allergy Clin Immunol. 1988 Dec;82(6):1037-41. doi: 10.1016/0091-6749(88)90141-8.","Christopher MA","J Allergy Clin Immunol","1988","1988/12/01","","","10.1016/0091-6749(88)90141-8"
"3192459","Use of narcotic antagonists to modify stereotypic self-licking, self-chewing, and scratching behavior in dogs","Dodman NH, Shuster L, White SD, Court MH, Parker D, Dixon R.","J Am Vet Med Assoc. 1988 Oct 1;193(7):815-9.","Dodman NH","J Am Vet Med Assoc","1988","1988/10/01","","",""
"3147046","Opioid peptides and primary biliary cirrhosis","Thornton JR, Losowsky MS.","BMJ. 1988 Dec 10;297(6662):1501-4. doi: 10.1136/bmj.297.6662.1501.","Thornton JR","BMJ","1988","1988/12/10","PMC1835218","","10.1136/bmj.297.6662.1501"
"3140862","Antagonism of morphine-induced respiratory depression with nalmefene","Konieczko KM, Jones JG, Barrowcliffe MP, Jordan C, Altman DG.","Br J Anaesth. 1988 Sep;61(3):318-23. doi: 10.1093/bja/61.3.318.","Konieczko KM","Br J Anaesth","1988","1988/09/01","","","10.1093/bja/61.3.318"
"3076856","Opiates, sleep and itch","Burch JR, Harrison PV.","Clin Exp Dermatol. 1988 Nov;13(6):418-9. doi: 10.1111/j.1365-2230.1988.tb00744.x.","Burch JR","Clin Exp Dermatol","1988","1988/11/01","","","10.1111/j.1365-2230.1988.tb00744.x"
"3067620","Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study","Ho SB, DeMaster EG, Shafer RB, Levine AS, Morley JE, Go VL, Allen JI.","Alcohol Clin Exp Res. 1988 Oct;12(5):705-12. doi: 10.1111/j.1530-0277.1988.tb00269.x.","Ho SB","Alcohol Clin Exp Res","1988","1988/10/01","","","10.1111/j.1530-0277.1988.tb00269.x"
"3026683","The role of endogenous opioids in congestive heart failure: effects of nalmefene on systemic and regional hemodynamics in dogs","Liang CS, Imai N, Stone CK, Woolf PD, Kawashima S, Tuttle RR.","Circulation. 1987 Feb;75(2):443-51. doi: 10.1161/01.cir.75.2.443.","Liang CS","Circulation","1987","1987/02/01","","","10.1161/01.cir.75.2.443"
"2991678","Binding of a new opiate antagonist, nalmefene, to rat brain membranes","Michel ME, Bolger G, Weissman BA.","Methods Find Exp Clin Pharmacol. 1985 Apr;7(4):175-7.","Michel ME","Methods Find Exp Clin Pharmacol","1985","1985/04/01","","",""
"2947253","Influence of nalmefene on energy balance and glucose regulation in Zucker rats","McLaughlin CL, Baile CA, Gingerich RL, Michel ME.","Physiol Behav. 1986;37(6):899-908.","McLaughlin CL","Physiol Behav","1986","1986/01/01","","",""
"2939305","Pro-opiomelanocortin-derived peptides in the testis: evidence for a possible role in Leydig and Sertoli cell function","Boitani C, Chen CL, Margioris AN, Gerendai I, Morris PL, Bardin CW.","Med Biol. 1986;63(5-6):251-8.","Boitani C","Med Biol","1986","1986/01/01","","",""
"2893982","Biological evaluation of compounds for their physical dependence potential and abuse liability. X. Drug testing programs of the Committee on Problems of Drug Dependence, Inc. (1986)","Jacobson AE.","NIDA Res Monogr. 1987;76:370-91.","Jacobson AE","NIDA Res Monogr","1987","1987/01/01","","",""
"2890074","An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice","Morley JE, Flood JF.","Life Sci. 1987 Nov 2;41(18):2157-65. doi: 10.1016/0024-3205(87)90534-0.","Morley JE","Life Sci","1987","1987/11/02","","","10.1016/0024-3205(87)90534-0"
"2765984","Opioid modulation of feeding and drinking in fowls","Savory CJ, Gentle MJ, Yeomans MR.","Br Poult Sci. 1989 Jun;30(2):379-92. doi: 10.1080/00071668908417159.","Savory CJ","Br Poult Sci","1989","1989/06/01","","","10.1080/00071668908417159"
"2745760","Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis","Monroe EW.","J Am Acad Dermatol. 1989 Jul;21(1):135-6. doi: 10.1016/s0190-9622(89)80353-6.","Monroe EW","J Am Acad Dermatol","1989","1989/07/01","","","10.1016/s0190-9622(89)80353-6"
"2717513","Isolation of a novel morphinan 3-O-diglucuronide metabolite from dog urine","Dixon R, Hsiao J, Hsu HB, Smulkowski M, Tze-Ming-Chan, Pramanik B, Morton J.","Pharm Res. 1989 Jan;6(1):28-32. doi: 10.1023/a:1015818316854.","Dixon R","Pharm Res","1989","1989/01/01","","","10.1023/a:1015818316854"
"2716954","Comparison of the duration of action of nalmefene and naloxone on the hypothalamic-pituitary axis of the rhesus monkey","VanVugt DA, Webb MY, Reid RL.","Neuroendocrinology. 1989 Mar;49(3):275-80. doi: 10.1159/000125128.","VanVugt DA","Neuroendocrinology","1989","1989/03/01","","","10.1159/000125128"
"2671240","The implication of opiates in the glucocorticoid-mediated inhibition of LH secretion in rats","Belhadj H, de Besi L, Bardin CW, Thau RB.","J Endocrinol. 1989 Aug;122(2):451-6. doi: 10.1677/joe.0.1220451.","Belhadj H","J Endocrinol","1989","1989/08/01","","","10.1677/joe.0.1220451"
"2645889","Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures","Barsan WG, Seger D, Danzl DF, Ling LJ, Bartlett R, Buncher R, Bryan C.","Am J Emerg Med. 1989 Mar;7(2):155-61. doi: 10.1016/0735-6757(89)90128-9.","Barsan WG","Am J Emerg Med","1989","1989/03/01","","","10.1016/0735-6757(89)90128-9"
"2641028","A dose run-up and safety evaluation of nalmefene HCl in human volunteers","Fudala PJ, Johnson RE, Heishman SJ, Cone EJ, Henningfield JE.","NIDA Res Monogr. 1989;95:451-2.","Fudala PJ","NIDA Res Monogr","1989","1989/01/01","","",""
"2550622","Pharmacological characterization of supersensitivity to naltrexone in squirrel monkeys","France CP, Morse WH.","J Pharmacol Exp Ther. 1989 Sep;250(3):928-36.","France CP","J Pharmacol Exp Ther","1989","1989/09/01","","",""
"2542355","Naloxone antagonism of corticotropin-releasing hormone stimulation of prolactin secretion in rhesus monkeys","Vanvugt DA, Webb MY, Reid RL.","J Clin Endocrinol Metab. 1989 Jun;68(6):1060-6. doi: 10.1210/jcem-68-6-1060.","Vanvugt DA","J Clin Endocrinol Metab","1989","1989/06/01","","","10.1210/jcem-68-6-1060"
"2315439","Effects of nalmefene on feeding in humans. Dissociation of hunger and palatability","Yeomans MR, Wright P, Macleod HA, Critchley JA.","Psychopharmacology (Berl). 1990;100(3):426-32. doi: 10.1007/BF02244618.","Yeomans MR","Psychopharmacology (Berl)","1990","1990/01/01","","","10.1007/BF02244618"
"2314151","Antagonism of fentanyl-induced respiratory depression with nalmefene","Moore LR, Bikhazi GB, Tuttle RR, Weidler DJ.","Methods Find Exp Clin Pharmacol. 1990 Jan-Feb;12(1):29-35.","Moore LR","Methods Find Exp Clin Pharmacol","1990","1990/01/01","","",""
"2277810","Actions of the opioid antagonist, nalmefene, and congeners on reperfusion cardiac arrhythmias and regional left coronary blood flow","Caldwell RW, Nagarajan R, Chryssanthis A, Tuttle RR.","Pharmacology. 1990;41(3):161-6. doi: 10.1159/000138713.","Caldwell RW","Pharmacology","1990","1990/01/01","","","10.1159/000138713"
"2243336","Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats","Faden AI, Shirane R, Chang LH, James TL, Lemke M, Weinstein PR.","J Pharmacol Exp Ther. 1990 Nov;255(2):451-8.","Faden AI","J Pharmacol Exp Ther","1990","1990/11/01","","",""
"2230942","Opiate antagonist nalmefene improves intracellular free Mg2+, bioenergetic state, and neurologic outcome following traumatic brain injury in rats","Vink R, McIntosh TK, Rhomhanyi R, Faden AI.","J Neurosci. 1990 Nov;10(11):3524-30. doi: 10.1523/JNEUROSCI.10-11-03524.1990.","Vink R","J Neurosci","1990","1990/11/01","PMC6570099","","10.1523/JNEUROSCI.10-11-03524.1990"
"2219678","Reversal of oxymorphone sedation by naloxone, nalmefene, and butorphanol","Dyson DH, Doherty T, Anderson GI, McDonell WN.","Vet Surg. 1990 Sep-Oct;19(5):398-403. doi: 10.1111/j.1532-950x.1990.tb01217.x.","Dyson DH","Vet Surg","1990","1990/09/01","","","10.1111/j.1532-950x.1990.tb01217.x"
"2212165","Nalmefene and pruritus","Harrison PV.","J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):530. doi: 10.1016/s0190-9622(08)81120-6.","Harrison PV","J Am Acad Dermatol","1990","1990/09/01","","","10.1016/s0190-9622(08)81120-6"
"2178593","Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia","Yum SW, Faden AI.","Arch Neurol. 1990 Mar;47(3):277-81. doi: 10.1001/archneur.1990.00530030043014.","Yum SW","Arch Neurol","1990","1990/03/01","","","10.1001/archneur.1990.00530030043014"
"2120527","Effects of opioid blockade with nalmefene in older impotent men","Billington CJ, Shafer RB, Morley JE.","Life Sci. 1990;47(9):799-805. doi: 10.1016/0024-3205(90)90552-3.","Billington CJ","Life Sci","1990","1990/01/01","","","10.1016/0024-3205(90)90552-3"
"2007323","Human pharmacology and abuse potential of nalmefene","Fudala PJ, Heishman SJ, Henningfield JE, Johnson RE.","Clin Pharmacol Ther. 1991 Mar;49(3):300-6. doi: 10.1038/clpt.1991.32.","Fudala PJ","Clin Pharmacol Ther","1991","1991/03/01","","","10.1038/clpt.1991.32"
"1980130","Dynorphin A-(1-17) induces alterations in free fatty acids, excitatory amino acids, and motor function through an opiate-receptor-mediated mechanism","Bakshi R, Newman AH, Faden AI.","J Neurosci. 1990 Dec;10(12):3793-800. doi: 10.1523/JNEUROSCI.10-12-03793.1990.","Bakshi R","J Neurosci","1990","1990/12/01","PMC6570042","","10.1523/JNEUROSCI.10-12-03793.1990"
"1965042","Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors","DeHaven-Hudkins DL, Brostrom PA, Allen JT, Lesko LJ, Ferkany JW, Kaplita PV, Mavunkel BJ, Rzeszotarski WJ, Steranka LR.","Pharmacol Biochem Behav. 1990 Nov;37(3):497-504. doi: 10.1016/0091-3057(90)90019-e.","DeHaven-Hudkins DL","Pharmacol Biochem Behav","1990","1990/11/01","","","10.1016/0091-3057(90)90019-e"
"1926426","Protective effect of nalmefene and naloxone on the ischemically damaged small bowel","Lopez J, Naujokat P, Xavier R, Walters W, Toledo-Pereyra LH.","Transplant Proc. 1991 Oct;23(5):2448-9.","Lopez J","Transplant Proc","1991","1991/10/01","","",""
"1926416","Role of opioid antagonists in the rat liver ischemia model","Naujokat P, Xavier R, Lopez J, Walters W, Toledo-Pereyra LH.","Transplant Proc. 1991 Oct;23(5):2426-7.","Naujokat P","Transplant Proc","1991","1991/10/01","","",""
"1883251","Lower pleasantness of palatable foods in nalmefene-treated human volunteers","Yeomans MR, Wright P.","Appetite. 1991 Jun;16(3):249-59. doi: 10.1016/0195-6663(91)90062-w.","Yeomans MR","Appetite","1991","1991/06/01","","","10.1016/0195-6663(91)90062-w"
"1803028","Comparison of a serotonin antagonist, opioid antagonist, and TRH analog for the acute treatment of experimental spinal trauma","Puniak MA, Freeman GM, Agresta CA, Van Newkirk L, Barone CA, Salzman SK.","J Neurotrauma. 1991 Fall;8(3):193-203. doi: 10.1089/neu.1991.8.193.","Puniak MA","J Neurotrauma","1991","1991/01/01","","","10.1089/neu.1991.8.193"
"1797032","Opioidergic, serotonergic, and dopaminergic manipulations and rats' intake of a sweetened alcoholic beverage","Hubbell CL, Marglin SH, Spitalnic SJ, Abelson ML, Wild KD, Reid LD.","Alcohol. 1991 Sep-Oct;8(5):355-67. doi: 10.1016/0741-8329(91)90573-f.","Hubbell CL","Alcohol","1991","1991/09/01","","","10.1016/0741-8329(91)90573-f"
"1661859","Evaluation of the sites of opioid influence on anterior pituitary hormone secretion using a quaternary opiate antagonist","Simpkins JW, Swager D, Millard WJ.","Neuroendocrinology. 1991 Oct;54(4):384-90. doi: 10.1159/000125918.","Simpkins JW","Neuroendocrinology","1991","1991/10/01","","","10.1159/000125918"
"1592876","Progesterone inhibits the estrogen-induced gonadotropin surge in the rhesus monkey independent of endogenous opiates","Van Vugt DA, Heisler LE, Reid RL.","J Clin Endocrinol Metab. 1992 Jun;74(6):1312-9. doi: 10.1210/jcem.74.6.1592876.","Van Vugt DA","J Clin Endocrinol Metab","1992","1992/06/01","","","10.1210/jcem.74.6.1592876"
"1487543","Opiate antagonists and eating behavior in humans: a review","de Zwaan M, Mitchell JE.","J Clin Pharmacol. 1992 Dec;32(12):1060-72.","de Zwaan M","J Clin Pharmacol","1992","1992/12/01","","",""
"1335562","Involvement of opioid receptors in nucleus tractus solitarii in modulating endotoxic hypotension in rats","Xu T, Wang T, Han J.","Neurosci Lett. 1992 Oct 26;146(1):72-4. doi: 10.1016/0304-3940(92)90175-7.","Xu T","Neurosci Lett","1992","1992/10/26","","","10.1016/0304-3940(92)90175-7"
"1333541","The pruritus of cholestasis and the opioid system","Jones EA, Bergasa NV.","JAMA. 1992 Dec 16;268(23):3359-62.","Jones EA","JAMA","1992","1992/12/16","","",""
"1321363","Ex vivo determination of opiate antagonist binding at mu-opioid ([3H]-DAGO) receptors in hypothalamic micropunches from maturing female rats: comparison between SDZ 210-096 and nalmefene","Landymore KM, Giles A, Wilkinson M.","Neuropeptides. 1992 Mar;21(3):175-82. doi: 10.1016/0143-4179(92)90042-u.","Landymore KM","Neuropeptides","1992","1992/03/01","","","10.1016/0143-4179(92)90042-u"
"1315182","Effects of naloxone and nalmefene in rat spinal cord injury induced by the ventral compression technique","Benzel EC, Khare V, Fowler MR.","J Spinal Disord. 1992 Mar;5(1):75-7. doi: 10.1097/00002517-199203000-00009.","Benzel EC","J Spinal Disord","1992","1992/03/01","","","10.1097/00002517-199203000-00009"
